17 19	70	110				الاست.	1	
Form P	IO-I		-			Application Number	09/460,216	
		Patent	and T	rademark (Office	Filing Date First Named Inventor	December 13, 1999	
INFAD	MAT	TION DISCLOSURE STA	TEM	A CHANG		Art Unit	Graham P. Allawa 1648	y et al
		sheets if necessary)	TEN	BAILE!	.\	Examiner Name	Jeffrey S. Parkin	
(OSC SCY	Ciai	sinceis ir necessary)			3	Attorney Docket No.	50875-F-PCT	
				AUG 2 3 2007	<u>,,,,</u>		US/JPW/AG/LAD	
	r —	<u> </u>		ATENT DO	MEN	rs		
Examiner Initials	Cite No. ¹		M	A-DD-YYYY	<u>. </u>	ne of Patentee or Appl	icant of Cited Docum	nent
		U.S. 6,025,154	10-	10-2004	Y. Li	et al.		
01		U.S. 6,265,184	07-	24-2001	P.W.	Gray et al.		
		U.S. 6,268,477	07-	31-2002	P.W.	Gray et al.		
		U.S. 6,488,375			1	mson et al.		
		U.S. 6,511,826		28-2003	L			
		U.S. 6,692,938	02-	17-2004	M. Sa	mson et al.		
·		U.S. 6,743,594	. I	01-2004				
		U.S. 6,972,126	12-	06-2005	G.P.	Allaway et al	L.	
		U.S. 6,800,447				mson et al.		
		U.S. 6,800,729	10-	05-2004	Y. Li	et al.		
		U.S. 5,449,608	ı			ung et al.		
		U.S. 6,261,763 B1	07-	17-2001	G.P.	Allaway et al	•	
		U.S. 6,528,625	03-	04-2003	L. Wu	et al.		
		U.S. 6,930,174	08-	16-2005	M. Sa	mson et al.		
		U.S. 6,100,087	08-	08-2000	J. Ro	ssi et al.		·····
		U.S. 5,939,320	. (ttman et al.		
		U.S. 6,258,527				ttman et al.		
4		U.S. 6,258,782	07-1	L0-2001	S. Ba	rney et al.		
		FO	REIGN	N PATENT D	OCIME	NTC		
xaminer Initials	Cite No.1	Foreign Patent Document Country Code Number Kind Code		Publication MM-DD-Y	Date	Name of Patentee or Docum		T6
		MO 92/01/E1						+-
()	\neg	WO 92/01451	-	02-06-19				+-
7		WO 95/16789 WO 97/28258		06-22-19				+
				08-07-19				-
		NO 97/44462		11-27-19	97			1
		NO 98/18826		05-07-19	98			
4		NO 01/55439		08-02-20	01			
CAMINER		A -		DATE CONSIDI	ERED	112/2007		

TEXAMINER: thinal if cliation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here it English Language Translation is attached.

Applicants: G.P. Allaway, et al. Serial No.: 09/460,216

Filed: December 13, 1999 Exhibit A

			·				
			(\cdot)			(·)	Page 2 of 19
For	n P	rO-1	449 U.S. Dep	artment of Con	merce	Application Number	09/460,216
Ì			•	nd Trademark (Filing Date	December 13, 1999
			•			First Named Inventor	Graham P. Allaway et al.
INF	ORN	TAN	TION DISCLOSURE STAT	TEMENT		Art Unit	1648
(Use	sev	eral	sheets if necessary)			Examiner Name	Jeffrey S. Parkin
							50875-F-PCT US/JPW/AG/LAD
			·	U.S. PATENT DOC	CUMENT	rs	
Exan		Cite No.1	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Nar	ne of Patentee or Appl	icant of Cited Document
			U.S. 6,692,938	02-17-2004	M. Sa	mson et al.	
7	7		U.S. 5,071,964	12-10-1991	M. Du	stin et al.	
			U.S. 5,091,513	02-25-1992	J. Hu	ston et al.	
			U.S. 5,215,913	06-01-1993	M.R.	Posner et al	•
			U.S. 5,225,539	07-06-1993	G.P.	Winter et al	•
\Box			U.S. 5,603,933	02-18-1997	V.A.	Dwyer et al.	
			U.S. 5,668,149	09-16-1997	S. Or	oszlan et al	•
			U.S. 5,817,767	10-06-1998	G.P.	Allaway et a	1.
			U.S. 5,854,400	12-29-1988	T. Ch	ang et al.	•

12-12-1989

01-30-2003

11-24-2005

06-02-2005

09-04-2003

12-23-2004

10-16-2003

05-22-2003

01-02-2003

L.E. Hood et al.

P.W. Gray et al.

P.W. Gray et al.

Combadiere et al.

C. Combadiere et al.

D. Littman et al.

L. Lopalco et al.

Y. Li et al.

L. Wu et al.

U.S. 4,886,743

U.S. 2003/0023044

U.S. 2005/0260565

U.S. 2005/0118677

U.S. 2003/0166870

U.S. 2004/0259785

U.S. 2003/0195348

U.S. 2003/0096221

U.S. 2003/0003440

Examiner Initials	Cite No.1	Foreign Patent Document Country Code ^t Number ^t Kind Code ^{f (Flames)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
X		WO 02/064612	08-22-2002	
U		WO 01/58915	08-16-2001	
		WO 01/58916	08-16-2001	
		WO 96/39437	12-12-1996	
		WO 97/22698	06-26-1997	
		WO 97/44055	11-27-1997	
V		wo 97/032019	09-04-1997	
EXAMINER SIGNATUR	-	h	DATE CONSIDERED	4 12 2007

*EXAMINER: Initial is citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents at www.uspto.gov, or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449

U.S. Department of Commerce Application Number Patent and Trademark Office Filing Date

Filing Date December 13, 1999 First Named Inventor Graham P. Allaway et al.

09/460,216

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Art Unit 1648

Examiner Name Jeffrey S. Parkin

Attorney Docket No. 50875-F-PCT

US/JPW/AG/LAD

		· · · · · · · · · · · · · · · · · · ·	U.S. PATENT DO	CUMENTS -
Examiner Initials	Cite No.	Document Number Number-Kind Code ^{3 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
Y		U.S. 2002/0150888	10-17-2002	P.W. Gray et al.
∇		U.S. 2004/0161739	08-19-2004	M. Samson et al.
		U.S. 2004/0230037	11-18-2004	P.W. Gray et al.
		U.S. 2004/0110127	06-10-2004	M. Samson et al.
		U.S. 2005/0154193	07-14-2005	V. Roschke et al.
		U.S. 2003/0100058	05-29-2003	V. Roschke et al.
		U.S. 2003/0166024	09-04-2003	C. Rosen et al.
		U.S. 2004/0151719	08-08-2004	Y. Li et al.
		U.S. 2001/0000241	04-12-2002	Y. Li et al.
		U.S. 2001/0046512	11-29-2001	V.M. Litwin et al.
		U.S _, . 2002/0048786	04-25-2002	C. Rosen et al.
		U.S. 2002/0061834	05-23-2002	C. Rosen et al.
		U.S. 2002/0110870	08-15-2002	M. Samson et al.
		U.S. 2003/0023044	01-30-2003	Y. Li et al.
		U.S. 2006/0029932	<u> </u>	G.P. Allaway et al.
		U.S. 2006/0140977		G.P. Allaway et al.
		U.S. 2002/0045161		G.P. Allaway et al.
•		U.S. 2004/0062767	04-01-2004	W.C. Olson et al.

	FOREIGN	PATENT I	OCUMENTS
--	---------	----------	----------

	xamine nitials	Cite No.1	Foreign Patent Document Country Code ¹ Number ² Kind Code ⁵ (Farm)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
	\nearrow		EP 9687002.1	03-01-1996		
T	U,	1	EP 96870102.9	08-06-1996		
T		1	EP 1145721 A2	10-17-2001		t
ļ.		1	EP 1146055 A2	10-17-2001		
			EP 1146122 A2	10-17-2001		
T		†	EP 1148126 A2	10-24-2001		
	7		EP 1148127 A2	10-24-2001		
E	AMINE	R	1	DATE CONSIDERED		

EXAMINER SIGNATURE DATE CONSIDERED W 12 200

*EXAMINER: Initial if clustion considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. It ind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

Form P	Form PTO-1449 U		J.S. Department of Commerce			Λp	Application Number		09/460,216	
]		Patent an	d T	rademark (Office	Filing Date			December 13, 1999	
						Fir	First Named Inventor		Graham P. Allaway et al.	
INFORI	TAN	ION DISCLOSURE STAT	ΈM	1ENT			Unit		1648	
(Use sev	eral	sheets if necessary)	•				miner N		Jeffrey S. Parkin	
					·-	Atte	orney Do	cket No.	50875-F-PCT US/JPW/AG/LAD	
·	,	Į.	J.S. P	ATENT DO	CUMEN	TS			- 1: - 1 - 23 1	
Examiner Initials	Cite No.	Document Number Number-Kind Code ^{2 (If known)}		olication Date 4-DD-YYYY	Na	me o	l Patento	e or Appl	leant of Cited Docum	ent
								 		
					<u> </u>					
										
					-					
								•	····	
										 .
										
		FOR	RICN	N PATENT D	OCUM	FNT	e			
Examiner Initials	Cite No.1	Foreign Patent Document Country Code*Number*Kind Code ^{5 (#)}		Publication MM-DD-Y	Date			atentee or Docur	Applicant of Cited nent	T ⁶
		EP 1149582 A2		10-31-20	001					
U ₁		EP 1199360 A2		04-24-20	002			 		
		EP 1482042 A1		12-01-20						
		EP 0815137		12-12-19						
		EP 0883687 B1		11-27-20						
4		CA 2216990		12-27-19	97					
EXAMINER SIGNATURI	<u> </u>			DATE CONSID		U	12	200)	
ind not consi of Codes of U ST.3). ⁴ For J of document	dered JSPT apanes by the	ath ficitation considered, whether or not confided copy of this form with next communication Documents at www.uspto.gov or the patent documents, the indication of the yappropriate symbols as indicated on the documentation is attached.	unicat MPEP ear of	ion to applicant. 901.04. ³ Enter (the reign of the	'Applican Office that Emperor m	t's un issued lust Di	ique citation of the document	on designation ment, by the serial numb	on number (optional). See two-letter code (WIPO Si er of the patent document.	e Kinds tandard 5 Kind

Form PT	O-144	9 U.S. Department of Commerce	Application Number	09/460,216	
	0-14-	Patent and Trademark Office	Filing Date	December 13, 1999	
		ratent and Trademark Office	First Named Inventor		
INFORM	IATIO	ON DISCLOSURE CITATION	Art Unit	1648	et al.
		s if necessary)	Examiner Name	Jeffrey S. Parkin	
		•	Attorney Docket No.	50875-F-PCT	
				US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS	•	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), tis	tle of the article (when app	ropriate), title of the	T ²
Initials	Ņo.'	item (book, magazine, journal, serial, symposium, catalo	g, etc.) date, page(s), volu	ne-issue number(s),	•
$\overline{}$		publisher, city and/or countr Abaza, M.S.I et al., (1992)	"Effects Of	Amino Acid	
1/		Substitutions Outside An Antigenic	Site On Protei	n Binding To	
$X \mid$		Monoclonal Antibodies Of Predeterm	ined Specificity	v Obtained By	
		Peptide Immunization: Demonstr	cation With Re	gion 94-100	
		(Antigenic Site 3) Of Myoglobin", Alexander, H. et al., (1992) "Al	J. Prot. Chem.	11(5):433-443	
1		Proteins", Proc. Natl. Acad. Sci.	reting The Ant	rgenicity Of	
1 1		Alkhatib et al., (1996) Abstr		nference O-	
		Retroviruses	se seu co	Surference Ou	
		Allan, J., (1997) "Human Immu	nodeficiency V	irus-Related	
1		Infections In Animal Model Syst	ems". In AIDS	: Biology.	
1 1		Diagnosis, Treatment And Prevention	on, 4th Edition,	Lippincott-	
		Raven Publishers, Philadelphia, Pp	15-27		
1		Allaway, G.P. et al., (1993) "Syne Envelope-Mediated Cell Fusion E	ergistic Inhibit	ion Of HIV-1	
1 1		Combination With Antibodies To gp	ol20 Or on41".	lolecules In	
		Retroviruses 9:581-587			
		Allaway, G.P. et al., (1995) "Expr	ession And Char	acterization	
- 1 - 1		Of CD4-IgG, A Novel Heterotetramer	That Neutralize	s Primary HIV	
+++		Type 1 Isolates", AIDS Res Hum Ret Amara, A. et al., (1997) "HIV Co	rovirus 11:533-	539	• •
1 1		Antiviral Principle: SDF-lα-Dependent	dent Internaliza	egulation As	
1 1		Chemokine Receptor CXCR4 Contrib	utes To Inhibi	tion Of HIV	
		Replication", J. Exp. Med. 186:139	-146		
1 • 1		Arthos, J. et al., (1989) "Identi	fication Of The	Residues In	
1		Human CD4 Critical For The Binding	Of HIV". Cell	57:469-481	
		Ashorn, P.A. et al., (1990) "Hu	man Immunodefic	iency Virus	
		Envelope Glycoprotein/CD4 Mediated	Fusion Of Nonp	rimate Cells	
		With Human Cells", J. Virol. 64:21	49-2156		
- 1 - 1		Attanasio, R. et al., (1991) "Anti- To Monoclonal Anti-CD4 Preparat	-Idiotypic Antib	ody Response	
1 1		Species", J. Immunol. 146:507-514	IONS IN NORMU	man Primate	
		Baba, M. et al., (1988) "Mechanis	sm Of Inhibitor	v Effect Of	
		Dextran Sulfate And Heparin (On Replication	Of Human	
1	ļ	Immunodeficiency Virus <i>In Vitro"</i> ,	Proc. Natl.	Acad. Sci.	
++		85:6132-6136 Baulerle, P.A. And Huttner, W.B., (1007\ "	0.15-515	
		A Trans-Golgi-Specific Protein M	iodification"	Sulfation Is	
		105:2655-2663		•	
		Benet et al. (1990) "Pharmacokine	tics: The Dynar	mics Of Drug	
₹	- 4	Absorption, Distribution And Eli	.mination" In	Goodman And	
	Ì,	Gilman's The Pharmacological Basis	Of Therapeutic	s, Gilman Et	
	1	El., Eds. Pergamon Press, New York	, Pp 3-32		
AMINER		\ DATE CONSIDERED	į.		

and not considered. Include copy of this form with next communication is to place a checkmalt here if English language Translation is attached.

orm Pf	0-1449 U.S. Department of Comme	rce Application Number	09/460,216		
	i awni and I i addinate Offi	-			
Patent and Trademark Office Patent and Trademark Office Patent and Trademark Office Patent and Trademark Office Filing Date Permber 13, 1999 First Named Inventor Graham P. Allaway et a Art Unit 1648 Examiner Name Jeffrey S. Parkin Attorney Docket No. S0875-F.PCT US/JPW/AG/LAD NON PATENT LITERATURE DOCUMENTS Examiner No. Item (book, magazine, journal, serial, symposhin, cutalog, etc) date, page(s), volume-issue number(s), publisher, city and/or country where published. Berger, E.A. et al. (1995) Abstract No. 002, 8 At Keystone Symposium Berger, E.A. et al., (1999) "Chemokine Receptors As HIV-1 Coreceptors: Roles In Viral Entry, Tropism And Disease", Ann. Rev. Immunol. 17:657-700 Bieniasz, P.D. et al., (1997) "HIV-1 Induced Cell Fusion Is Mediated By Multiple Regions Within Both The Viral Envelope And The CCR5 Co-Receptor", EMBO 16:2599-2609 Blanpain, C. et al., (1999) "Multiple Charged And Aromatic Residues In CCR5 Amino-Terminal Domain Are Involved In High Affinity Binding of Both Chemokines And HIV-1 Env Protein", J. Biol. Chem. 274:34719-34727 Brelot, A. et al., (1997) "Nole Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity", J. Virol. 71:4744-4751 Broder, C.C. et al., (1993) "The Block To HIV-1 Envelope Glycoprotein-Mediated Expressing Human CD4 Can Be Overcome By A Human Cell Component(s)", Virol. 193:483-491 Burkly, L. et al., (1995) "Synergistic Inhibition Of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion And Infection By An Antibodies", J. Virol. 69:4267-4273 Burton, D.R. et al., (1994) "Efficient Neutralization Of					
J. N. SCYCI W	intensit necessary)				
	,	Tribblidg Docker 110.			
	NON PATENT LITERATU	RE DOCUMENTS			
	No. titem (book, magazine, journal, serial, symposium,	catalog, etc.) date, page(s), vol			
\searrow		stract No. 002,	8 At Keystone		
0			The Chemokine		
T	Coreceptors: Roles In Viral En	"Chemokine Receptory, Tropism And	tors As HIV-1 Disease", Ann.		
	Mediated By Multiple Regions Wi The CCR5 Co-Receptor*, EMBO 16:	thin Both The Vira 2599-2609	l Envelope And		
	Residues In CCR5 Amino-Termina Affinity Binding Of Both Chemok	l Domain Are Inv	olved In High		
	Brelot, A. et al., (1997) "Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity", J. Virol. 71:4744-4751				
	Glycoprotein-Mediated Membran Expressing Human CD4 Can Be Component(s)", Virol. 193:483-4	e Fusion In A e Overcome By A 91	Animal Cells A Human Cell		
	Immunodeficiency Virus Type 1 Cell Fusion And Infection By A Combination With Anti-gp-120 Ar	Envelope Glycopro n Antibody To CD	otein-Mediated 4 Domain 2 In		
	Primary Isolates Of HIV-1 By Antibody", Science 266:1024-10	A Recombinant Hum 27	an Monoclonal		
	Busso, M. et al., (1991) "HI Requires The Formation Of Conjug Uninfected T-Cells In Vitro",	gates Between Virus AIDS 5:1425-1432	s-Infected And		
	Camerini, D. et al., (1990) "A Mediated Syncytium Formation L Site", Cell 60:747-754 Cammack, N., (1999) "Human Immu	ies Outside The	Virus Binding		
	And Chemokine Receptors: A New Chem. Chemother. 10:53-62 Capon, D.J. et al., (1989) "Des	Therapeutic Targ	et", Antivir.		
4	AIDS Therapy", Nature 337:525-	531	aunesions For		
AMINER GNATURI		1/12/2007			
l not conside	Inutial if citation considered, whether or not citation is in conformance. Include copy of this form with next communication to applicant. Include copy of this form with next communication to applicant. Include copy of this form with next communication to applicant. Include the communication is attached.	e with MPEP 609: Draw line thro Applicant's unique citation design	ugh citation if not in conformance nation number (optional). ² Applic		

orm PT	O-144		Application Number Filing Date	09/460,216 December 13, 1999
		Patent and Trademark Office		Graham P. Allaway et :
NFORM	IATIC	ON DISCLOSURE CITATION	Art Unit	Graham P. Allaway et :
lse severa	ıl sheet:	if necessary)	Examiner Name	Jeffrey S. Parkin
				50875-F-PCT
		**************************************		US/JPW/AG/LAD
		NON PATENT LITERATURE	DOCUMENTS	
xaminer Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), (it item (book, magazine, journal, serial, symposium, catalo publisher, city and/or country	g, etc.) date, page(s), volum	ropriate), title of the ne-issue number(s),
1		Chams, V. et al., (1992) "Simple As	ssay To Screen F	or Inhibitors
	^	Of Interaction Between The Hun		iency Virus
\mathcal{A}		Envelope Glycoprotein And Its		ptor, CD4",
(I)		Antimicrob Agents Chemother. 36(2)		
· 1		Chan, D.C. et al., (1998) "Evidence	e That A Promine	ent Cavity In
1		The Coiled Coil Of HIV Type 1 of	gp41 Is An Att	ractive Drug
		Target", Proc. Natl. Acad. Sci. 95	:15013-15617	
		Chan, D.C. et al., (1998) "HIV Ent 93:681-684	•	
		Charo, I.F. et al., (1994) "Molec	ular Cloning An	d Functional
		Expression Of Two Monocyte Chemoat	tractant Proteir	1 Receptors
1 1		Reveals Alternative Splicing Of Th	ne Carboxyl-Term	inal Tails",
		Proc. Natl. Acad. Sci. 91:2752-275	11 7-	
1 1		Chen, Z. et al., (1997) "Genetion Simian Immunodeficiency Virus Use	cally Divergent	Strains Of
]		Entry", J. Virol. 71(4):2705-2714	CCV2 WA W CO.	receptor tot
/		Clapham, P.R. et al., (1989)	"Soluble CD4	Blocks The
1 1		Infectivity Of Diverse Strains Of	HIV And SIV For	T Cells And
1 1		Monocytes But Not For Brain And Mus	scle Cells", Nat	ure 337:368-
1		370		
1	•	Clapham, P.R. et al., (1991)	"Specific Co	ell Surface
l i	•	Requirements For The Infection Of Immunodeficiency Virus Types 1 And	CD4-Positive Ce	lis By Human
		Virus*, Virol. 181:703-715	s of sturent tum	modericiency
		Co. M.S. et al., (1991) "Humanize	ed Antibodies Fo	or Antiviral
		Therapy" Proc. Natl. Acad. Sci. 88	:2869-2873	
\		Combadiere, C. et al., (1995)	"Cloning And	Functional
		Expression Of A Human Eosinophil Biol. Chem. 270:16941-16494	CC Chemokine R	eceptor*, J.
├		Combadiere, C. et al., (1996)	"Cloning And	Functions?
1 1		Expression Of CC CKR5, A Human Mon	"Cloning And ocvte CC Chemok	Functional
		Selective For MIP-1α, MIP-1β, And	RANTES", J. L	eukoc. Biol.
		60:147-152		
] [eceptor Use
1 1		Correlates With Disease Progre		·1 Infected
 		<pre>Individuals*, J. Exp. Med. 185:621 Cormier, E. G. et al., (2000) "Sp</pre>		in 05 0005
1 1		Amino-Terminal Domain Peptides Con	taining Sulfatur	rosines With
V		HIV-1 Envelope Glycoprotein gp120	", Proc. Natl.	Acad. Sci.
		97-5762-5767	1	
AMINE	t	DATE CONSIDERED .		
SNATUR	E		2 200	
KAMINER	: Initial i	quation considered, whether or not citation is in conformance with	MPEP 609: Draw line through	n citation if not in conformation
not conside	ered Inch	de copy of this form with next communication to applicant. Applic	ant's unique citation decimant	!

\$

Form PT	0-144	9 U.S. Department of Commerce	Application Number	09/460,216	
			Filing Date	December 13, 1999	
		•	First Named Inventor	Graham P. Allaway	et al.
NFORM	IATIC	ON DISCLOSURE CITATION	Art Unit	1648	
		if necessary)	Examiner Name	Jeffrey S. Parkin	
				50875-F-PCT	
				US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, catal publisher, city and/or country	og, etc.) date, page(s), volu	propriate), title of the me-issue number(s),	Т
		Crowe, S.M. et al., (1992) "Hu		iency Virus-	
\ \	•	Infected Monocyte-Derived Macropha			
		Fuse With CD4 Lymphoid Cells In V	itro: A Possible	Mechanism Of	
		T Lymphocyte Depletion In Vivo",	Clin. Immunol	Immunopathol.	
V		65(2):143-151			
		Crump, M.P. et al., (1997) "Solut		.	
1		Functional Activity Of Strom			
1		Disassociation Of CXCR4 Activation Of HIV-1", EMBO 16:6996-7007	rrom Binding A	nd Inhibition	
		Cushman, M. et al., (1991) "Prepar	ation And Anti-L	ITV Activities	
		Of Aurintricarboxylic Acid Fract			
		Correlation Of Antiviral Potency			
		Med. Chem. 34:329-337	With Holeculus	weight, o.	
		Dalgleish, A.G. et al., (1984)	The CD4 (T4) A	ntigen Is An	
1 1		Essential Component Of The Recept			
		Nature 312:763-766		İ	
		Dalgleish, A.G., (1995) "HIV And	CD26", Nat. Med	. 1:881-882	
1 1		De Rossi, A. et al., (1995) "S	ynthetic Peptio	des From The	
-		Principle Neutralizing Domain Of	Human Immunodef	iciency Virus	
1 1		Type 1 (HIV-1) Enhance HIV-1 Infec	tion Through A	CD4-Dependent	
		Mechanism*, Virology 184:187-196			
l i		Dean, M. et al., (1996) "Genetic R			
1 1		And Progression To AIDS By A D Structural Gene*, Science 273:185		Of The CKR5	
		Deen, K.C. et al., (1988) "A Solu		1/D4) Drotoin	
1 1		Inhibits AIDS Virus Infection", No.		(14) Procein	
1-1		Deng, X. et al., (1999) "A Synthet	ic Pentide Deriv	red From Human	
		Immunodeficiency Virus Type 1	gp120 Downre	gulates The	
		Expression And Function Of Chemok	ine Receptors C	CR5 And CXCR4	
		In Monocytes By Activating The	7-Transmembran	e G-Protein-	
		Coupled Receptor FPRL1/LXA4R", Blo			
		Dettin, M. et al., (2003) "CCR5 N-			
		HIV-1 Infection By CXCR4 Up-Regula	tion", Biochem.	Biophys. Res.	
		Commun. 307(3)640-646	tial Character	777 1 8	
] }		Dimitrov, D.S. et al., (1991) "Ini	Liai Stages Uf H	TA-T FUAGIODE	
Glycoprotein-Mediated Cell Fusion Monitored By A New Assay Based On Redistribution Of Fluorescent Dyes*, AIDS Res Hum					
		Retroviruses 7(10):799-805	,	nes nul	
	1.00		e CCR5 Receptor	Acts As An	
TI		Alloantigen In CCR5A32 Homozygous		dentification	
V		Of Chemokine And HIV-1 Blocking Hu			
		Acad. Sci. 95(9):5241-5245	1		
XAMINE	1 3	DATE CONSIDERED			
IGNATUR		h (2	7,000		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Unclude copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

				Page 9 o	of 19
Form PT	'O-144	9 U.S. Department of Commerce	Application Nunicipi	09/460,216	
		Patent and Trademark Office	Filing Date	December 13, 1999	
ì		The state of the s	First Named Inventor		
INFORM	AATIC	ON DISCLOSURE CITATION	Art Unit	1648	et al.
		s if necessary)		1	
Cose sever	ai Silect	in decessary)	Examiner Name	Jeffrey S. Parkin	
			Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS		
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), ti	itle of the article (when ann	ronriste) title of the	T ²
Initials*	No.1	item (book, magazine, journal, serial, symposium, catale publisher, city and/or countr	og, etc.) date, page(s), volun ry where published.	ne-issue number(s),	ı
		Donzella, G.A. et al., (1998)	"AMD3100, A Sma	all Molecule	
4		Inhibitor Of HIV-1 Entry Via The (4:72-77			
		Doranz, B.J. et al., (1997) "Two	Distinct CCR5	Domains Can	
		Mediate Co-Receptor Usage By Humar 1°, J. Virol. 71:6305-6314			
		Dragic, T. et al., (1992) "Complem	mentation Of Muri	ne Cells For	
		Human Immunodeficiency Virus Enve	elope/CD4-Mediat	ed Fusion In	
		Human/Murine Heterokaryons", J. V. Dragic, T.V. et al., (1993) "	1rol. 66(8):4794	-4802	
		Membrane Fusion Mediated By	The Envelopes	rements For Of Human	
		Immunodeficiency Virus Types 1 An			
		2359		07(47.2335-	
		Dragic, T.V. et al., (1995) "Prot	teinase-Resistan	t Factors In	
		Human Erythrocyte Membranes Mediat	e CD-4 Dependent	: Fusion With	
		Cells Expressing Human Immunodefic Glycoproteins", J. Virol. 69:1013-	-1018		
		Dragic, T.V. et al., (1998) "Amir	no-Terminal Subs	titutions In	
1 1		The CCR5 Coreceptor Impair	gp120 Binding	And Human	
		Immunodeficiency Virus Type 1 Entr Dragic, T.V. et al., (2000) "A	Pinding Posters	(1):279-285 For 2 Const3	
		Molecule Inhibitor Of HIV-1 Entr	ov Within The T	ransmembrane	
		Helices Of CCR5", Proc. Natl. Acad	d. Sci. 97(10):5	639-5644	
		Ebadi, M., (1998) "The Pharmacokin	etic Basis Of Th	erapeutics".	*
1 1		In CRC Desk Reference Of Clinical	Pharmacology, CF	C Press LLC,	
		Boca Raton, Pp.:1-7			
1 1		Eckert, D.M. et al., (1999) "Inhib Of D-Peptide Inhibitors That Ta	oiting HIV-1 Entr	y: Discovery	
1 1		Pocket", Cell 99:103-115	arget the gp41	Colled-Coll	
		Eugene-Olsen, J. et al., (1997) "H	leterozygosity Fo	r A Deletion	
1 1	i i	In The CKR-5 Gene Leads To Prolo	nged AIDS-Free	Survival And	
11		Slower CD4 T-Cell Decline In A	Cohort Of HIV-	Seropositive	
		Individuals", AIDS 11:305-310			
		Farzan, M. et al., (1998) "A Tyro Terminus Of CCR5 Is Important For	osine-Rich Regio	n In The N-	
11	- 1	Type 1 Entry And Mediates Associat	ion Retween on 12	O And CCP5*	
		J. Virol. 72:1160-1164	Jeeneen gpiz	o Alia cola ,	
		Farzan, M. et al., (1999) "Tyrosi Terminus Of CCR5 Facilitates HIV-l	ine Sulfation Of Entry", Cell 9	The Amino-	
1		Farzan, M. et al., (2000) "A Tyrosi		T T	
A	ŀ	The N Terminus Of CCR5 Interacts Wi	ith A CD4-Enhance	ed Epitope Of	
	- 1	The HIV-1 gp 120 Envelope Glyco	protein And Inh	ibits HIV-1	
		Entry", J. Biol. Chem. 275:33416-3	3521		
EXAMINER		DATE CONSIDERED			
SIGNATUR		1	12/2007		
EXAMINER	: bnitjal if	ditation considered, whether or not citation is in conformance with	h MPEP 609: Draw line throug	h citation if not in conform	nince.

*EXAMINER: Initial if ditation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark tere if English language Translation is attached.

Earn W	/A 1.4.4	0 110 044 00	Application Number	00/460 216			
Form PI	U-144			09/460,216			
1		Patent and Trademark Office	Filing Date	December 13, 1999			
			First Named Inventor		et al.		
ł		ON DISCLOSURE CITATION	Art Unit	1648			
(Use sever	ıl sheets	if necessary)	Examiner Name	Jeffrey S. Parkin			
			Attorney Docket No.	50875-F-PCT			
			1	US/JPW/AG/LAD			
		NON PATENT LITERATURE	DOCUMENTS		 		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), t item (book, magazine, journal, serial, symposium, catal publisher, city and/or count	og, etc.) date, page(s), volu		T²		
K		Feng, Y. et al., (1996) Abstr Symposium					
0		Ferrer, M. et al., (1999) "Select Cell Entry Inhibitors From Biased Non-Natural Binding Elements", Na	d Combinatorial	Libraries Of			
		Fouchier, R.A. et al., (1994) " Determined At Multiple Levels Of ' J. Clin. Invest. 94:1806-1814	HIV-1 Macrophag	e Tropism Is			
		Fouts, T.R. et al., (1997) "Neutralization Of The Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL By Human Monoclonal Antibodies Correlates With Antibody Binding To The Oligomeric Form Of The Envelope Glycoprotein Complex", J. Virol. 71:2779-2785					
		Freed, E.O. et al., (1991) "I Residues In The Human Immunodefic Neutralizing Determinant That Ar Res. Hum. Retroviruses. 7(10):807 Fradd, F. and Mary, M.E. (1989) "	iency Virus Typ e Involved In I -811	e 1 Principal Fusion", <i>AIDS</i>			
		Guide By Shearman Lehaman Hutton"		2)			
		Structure And Function" Fundament Lippincott-Raven Publishers, Phil	al Immunology, adelphia, Pp. 31	4th Edition, 7-74	•		
		Furuta, R.A. et al., (1998) "Captu Conformation Of HIV-1 gp41", Natus	re Struct. Biol.	5(4):276-279			
		Gauduin, M.C. et al., (1996) "Effe Of Human Immunodeficiency Viru Recombinant Immunoglobulin Molecu	s Type 1 in les", J. Virol.	Plasma By 70:2586-2592			
		Gauduin, M.C. et al., (1997) *Pass Monoclonal Antibody Protects hu-PB By Primary Isolates Of HIV-1*, Na	L-SCID Mice Agai t. Med. 3:1389-1	nst Challenge 1393			
		Ghorpade, A. et al, (1998) "Role CCR3 And CCR5 In Human Immunodefic Of Monocytes And Microglia", J. V.	iency Virus Typ irol. 72:3351-33	e 1 Infection 861			
		Golding, H. et al., (1992) "LFA-1 Involved In The Early Stages (Membrane Fusion <i>", AIDS Res. Hum</i> .	Of HIV-1 <i>env-</i> M Retroviruses 8:1	ediated Cell 1593-1598			
4		Graham, B.S. et al., (1995) "Car Engl. J. Med. 333:1331-1339	ndidate AIDS Va	ccines", New			
EXAMINE SIGNATUI		DATE CONSIDERED W	2 20m				
		f citation considered, whether or not citation is in conformance with copy of this form with next communication to applicant. 'App					

	~ 4.4.4		Ta at at a	lance con a c	
Form P T	()-144			09/460,216	
		Patent and Trademark Office	Filing Date	December 13, 1999	
			First Named Inventor		y et al.
		ON DISCLOSURE CITATION	Art Unit	1648	
Use severa	ıl sheet	s if necessary)		Jeffrey S. Parkin	
				50 875-F-PCT US/JPW/AG/LAD	
`		NON PATENT LITERATURE		CONT WINGILAD	
	611A.	T i			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), til item (book, magazine, journal, serial, symposium, catalo publisher, city and/or countr	g, etc.) date, page(s), volum y where published.	ne-issue number(s),	T ²
7		Grene, E. et al., (2001) "Anti-CCR			
2		Positive Individuals", Human Immur	101. 62(2):143-1	45	
/ /		Harouse, J.M. et al., (1991) "Inhi	ibition Of Entry	Of HIV-1 In	
ノ、1		Neural Cell Lines By Antibodies Ag			
		Science, 253:320-323			
		Harrington, R.D. And Geballe, Requirement For Human Immunodefici			
		A CD4-Expressing Human Cell Line",			
\neg		He, J. et al., (1997) "CCR3 And CCI	R5 Are Co-Recepto		
		Infection Of Microglia*, Nature 38	35: 645-649		
		Heath, et al., (1997) "Chemokin	e Receptor Usa	ge By Human	
		Eosinophils. The Importance Of (Antagonistic Monoclonal Antibody",	CCR3 Demonstrat	ed Using An	
- 1 - 1		Heidenreich, O. et al., (1995)			
		Technology To Therapeutics*, Mol.	Med. Today 1:12	8-133	
		Hildreth, J.E. et al., (1989) "	Involvement Of	A Leukocyte	
		Adhesion Receptor (LFA-1) In HIV-I Science 244:1075-1078	Induced Syncytiu	m Formation"	
		Hill, C.M. et al., (1998) "The Ami	no Terminus Of H	uman CCR5 Is	
1 1		Required For Its Function As A Rec	eptor For Diver	se Human And	
.		Simian Immunodeficiency Virus Envel 248:357-371	tope Glycoprotein	is', Virology	
		Hirata, Y., (1989) "Characteri		-6 Receptor	
		Expression By Monoclonal And Polycl 143(9):2900-2906			_
11		Hirsch, M.S. et al., (1997) "Antir	etroviral Thera	py" In AIDS:	
		Biology, Diagnosis, Treatment, An Lippincott-Raven Publishers, Phila	delphia Po. 49	sen Ealtion, 5-508	
		Hwang, S. et al., (1991) "Identif	ication Of The	Envelope V3	
		Loop As The Primary Determinant	Of Cell Tropism	In HIV-1,"	
		Science 253:71-74	agivo T		
		Jacobson, J.M. et al., (1993) "Pa Treatment Of Advanced Human Immuno	deficiency Virus	Infection"	
		J. Infect. Dis. 168:298-305		ł	
[Jacobson, J. et al., (1999) "Resu	lts Of A Phase	I Trial Of	
		Single-Dose PRO 542, A Novel Abstracts Of The 39th Interscience	Conference On A	HIV Entry",	
		Agents And Chemotherapy 14			
		Ji, H. et al., (1999) "Inhibition	Of Human Immu	nodeficiency	
•		Virus Type 1 Infectivity By The gp Hydrophobic Cavity In Membrane Fws			
EXAMINE			1011, U. VIIOI	73.0370-0300	
IGNATUR		DATE CONSIDERED	2 2007		
	$\overline{}$	f citation considered, whether or not citation is in conformance with		h aitation if ant in anofas	

• EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark nere if English language Translation is attached.

,		• • • • • • • • • • • • • • • • • • • •	- Value				
Form PT	0-1449			09/460,216			
		Patent and Trademark Office	Filing Date	December 13, 1999			
			First Named Inventor	Graham P. Allaway et a	ıl.		
INFORM	NFORMATION DISCLOSURE CITATION Use several sheets if necessary Art Unit 1648 Examiner Name 196frey S. Parkin						
(Use severa	Jeffrey S. Parkin						
	Attorney Docket No. 50875-F-PCT						
		· · · · · · · · · · · · · · · · · · ·	<u> </u>	US/JPW/AG/LAD			
		NON PATENT LITERATURE	E DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), t item (book, magazine, journal, serial, symposium, catal publisher, city and/or count	log, etc.) date, page(s), volu ry where published.	me-issue number(s),	T²		
		Jiang, S. et al., (1993) "HIV-1 Nature 365: 113					
		Karwowska, S. et al., (1991) "P Treatment And Prevention Of HIV I 2:31-48	infection", Bio	tech. Therap.			
		Katinger, H., (1994) "Human Monoc Immunotherapy Of HIV-1" Antibiot.	Chemother. 46:	25-37			
		Keller, P.M. et al., (1977) "A Fl Of Cell Fusion" <i>J. Cell Sci</i> . 28:1	67-177				
		Kilby, J.M. et al., (1998) "P Replication In Humans By T-20, A Mediated Virus Entry", Nat. Med.	A Peptide Inhibi 4:1302-1307	tor Of gp41-			
		Konigs, C. et al. (2000) "Monoc Phage-Displayed Random Peptide L Chemokine Receptor CCR5: Impl Structure Of The Receptor And For For HIV-1 gp120", Eur. J. Immnol.	ibrary Reveals lications For r An N-Terminal	Mimotopes Of The Tertiary Binding Site			
		Konishi, K. et al., (2000) "Synt Chemokine Receptor CCR5 And Their HIV-1 Infection", Chem. Pharm. Bu	hesis Of Peption	des Mimicking fects Against			
		Koup, R.A. et al., (1996) *Definin HIV-1 Transmission In Hu-PBL-SCID	ng Antibody Prote	ection Against	,.		
		Kwong P.D. et al., (1998) "Struct Glycoprotein In Complex With The (Human Antibody", Nature 393:648-6	ure Of An HIV g CD4 Receptor And	p120 Envelope			
		Laal, S. et al., (1994) "Synergi: Immunodeficiency Virus Type 1 Monoclonal Antibodies", <i>J. Virol</i>	stic Neutraliza By Combinatio 68:4001-4008	ns Of Human			
		Lacasse, R.A. et al., (1999) "Pusi Neutralization Of Primary Isolates	Of HIV", Science	e 283:357-362			
		Lee, B. et al., (1999) "Epitop Multiple Conformational States A Structures Involved In Chemokine C Chem. 274:9617-9626	nd Distinct But Coreceptor Functi	on", J. Biol.			
		Lehner, T. et al., (2001) "Immunoo Domains Of C-C Chemokine Receptor Simian Immunodeficiency Or HIV 166(12):7446-7455	5 And The In Vit Infectivity",	ro Effects On J. Immunol.			
7		Li, A. et al., (1997) "Synergistic SIV/HIV Type 1 Virus With Combinat Envelope Monoclonal Antibodies Or Res. Hum. Retroviruses 13:647-56	ions Of Human Ar	ti-HIV Type 1			
EXAMINE SIGNATUI		DATE CONSIDERED V	2 2007				
*EXAMINE	R: Initial i	citation considered, whether or not citation is in conformance wi	th MPEP 609: Draw line thro	igh citation if not in conforman	nce]		

*EXAMINER: Iditial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmapt here if English language Translation is attached.

		N. 100	المدر المراد الم	loouso ses				
0.5. Department of Commerce				09/460,216	-			
	Patent and Trademark Office Filing Date December 13, 1999 First Named Inventor, Graham P. Allaway							
	First Named Inventor Graham P. Allaway et NEORMATION DISCLOSURE CITATION Art Unit 1648							
1	TORMATION DISCESSERE CITATION							
(Use severi	se several sheets if necessary) Examiner Name Jeffrey S. Parkin Parkin							
	Attorney Docket No. 50875-F-PCT US/JPW/AG/LAD							
		NON PATENT LITERATURE		iongt wittomic				
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), ti		concinte) title of the	T ²			
Initials	Initials No. item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
		Li, A.H. et al., (1998) "Synergist						
		Human Immunodeficiency Virus SHIV- Combination Of Human Monoclonal						
		Antihuman Immunodeficiency Virus						
		Virol. 72:3235-3240	-1,p	,				
		Mack, M. et al., (1998) "Aminooxy						
1		Internalization But Inhibits Rec						
		Mechanisms Of HIV Infectivity", J. Mackay, C.R., (1996) "Chemokir						
		Chemotaxis*, J. Exp. Med 84: 799-8		And T Cell				
		Maddon, P.J. et al., (1986) "The Te		he AIDS Virus				
		Receptor And Is Expressed In The I	immune System And	d The Brain",				
		Cell 47:333-348						
		Markosyan, R.M. et al., (2002) "Th HIV-1 Entry Env-Mediated Cell-Cell						
		Of gp41 Ectodomain", Virology 302:		ibinant Cores				
		Mateu, M.G. et al. (1992) "Non-A	dditive Effects					
		Amino Acid Substitutions On Ant		lecognition",				
		European J. Immunol. 22(6):1385-13						
		Max, E., "Immunoglobulins: Molectinunology, 4th Edition. Lin	pincott-Raven	Fundamental Publishers,				
		Philadelphia, 1999 Pp. 11-182						
		Mitsuya, H. et al., (1985) *Pro						
		Infectivity And Cytopathic Effectivity						
		Retroviruses In Human Lymphoma Leu Tokyo/VNU Science Press, Utrecht B		Soc. Press,				
		Mittler, R.S. et al. (1989) "Syne		IV gp120 And				
		gp120-Specific Antibody In Blockin						
		Science 245:1380-1382	2-11-2-1					
		Mohan, P. et al., (1992) "Sulfonic Of Human Immunodeficiency Virus						
		18:139-150	LIMITALICATE , MII	CIVILLI RES.				
		Mosier, D.E., (1990) "Immunodefic						
		Human Lymphoid Cells: New Models						
		Immunobiology And Infectious Dis	seases", J. Cl:	in. Immunol.				
 - 		Nagasawa, T. et al., (1994) "Molect	ular Cloning And	Structure Of				
		A Pre-B-Cell Growth-Stimulating F	• -					
		Sci. 91:2305-2309	·					
		Nagashima, K.A. et al., (2001) "H						
		Type 1 Entry Inhibitors PRO 5 Synergistic In Blocking Virus-Cel						
10	_	Infect. Dis. 183:1121-1125						
EXAMINE		DATE CONSIDERED	12 2002	•				

*EXAMINER: Initial if vitation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

Form PT	0.144	9 U.S. Department of Commerce	Application Number	09/460,216	
COLINEA	()-144	Patent and Trademark Office		December 13, 1999	
		ratent and trademark Office		Graham P. Allaway et	al
NFORM	IATIC	ON DISCLOSURE CITATION	Art Unit	1648	
		if necessary)	Examiner Name	Jeffrey S. Parkin	
		· · · · · · · · · · · · · · · · · · ·		50875-F-PCT	
			<u> </u>	US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS		
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), ti			T ²
Initials'	No.1	item (twok, magazine, journal, serial, symposium, catak		ne-issue number(s),	
}	,	publisher, city and/or countr Nakano, T. et al., (1995) "Vascula		Cell-Derived.	
κ		Gla-Containing Growth-Potentiating			
\times		Growth Factors", J. Biol. Chem. 2			
		Neote, K. et al., (1993) "Mol			
-		Expression, And Signaling Charact	eristics Of A C	-C Chemokine	
		Receptor", Cell 72:415-425	 		
1 1		O'Brien, W.A. et al., (1990) "HI			
1 1		Phagocytes Can Be Determined By Re- CD4-Binding Domain*, Nature 348:69		utside Of The	
		Olson, W.C. et al., (1999) *Diffe		ion Of Human	
1 1		Immunodeficiency Virus Type 1 Fus			
1 1		Chemokine Activity Of Monoclonal A			
		73:4145-4155			
		Oppermann, M. (2004) "Chemokine Re			
		Structure, Function, And Regulati 1210			
1 1		Parren, P.W. et al., (2001) "Antib			
1 1		Vaginal Challenge With A Pa Immunodeficiency Virus At Seru	thogenic R5	Simian/Human ng Complete	
		Neutralization In Vitro" J. Virol.		ing complete	
		Partidos, C. et al., (1992) "Th		ientation Of	
- 1 1		Epitopes On The Immunogenicity Of			
		Representing Measles Virus Pro	tein Sequences	, Molecular	
		Immunology 29(5):651-658	an In Consumb D		
[]		Peden, K. et al., (1991) "Chang Passage In Tissue Culture Of Viru			
		Molecular Clones Of HIV-1LAI, HIV-			
\		185:661-672			
		Poignard, P. et al., (1999) "Ne			
		Limited Effects On The Control Of	Established HIV	7-1 Infection	
		In Vivo", Immunity 10:431-438	alization of uni	1 D. P105 3	_
		Posner, M.R. et al., (1993) "Neutra Human Monoclonal Antibody To The C			
- { }		Acq. Immune Defic. Synd. 6:7-14	Diming Dice	or abiro , o.	
-		Power, C.A. et al., (1995) "Molec	ular Cloning An	d Functional	
	,	Expression Of A Novel CC Chemokine			
		Basophilic Cell Line*, J. Biol. Cl			
11		Proudfoot, A.E. et al., (1996) "Ex RANTES By The Retention Of The Ini			
		Potent Antagonist", J. Biol. Chem.			
- L		Queen, C. et al., (1989) "A Human			
•		The Interleukin 2 Receptor", Proc 10033			
EXAMINE		DATE CONSIDERED	12 2207		

*EXAMINER: Initial if criation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). Applicant is to place a checkmark there if English language Translation is attached.

Application Number 09/460,216
First Named Inventor Graham P. Allaway et al.
Art Unit 1648 Examiner Name Jeffrey S. Parkin Attorney Docket No. 50875-F-PCT US/JPW/AG/LAD
Examiner Name Jeffrey S. Parkin Attorney Docket No. 50875-F-PCT US/JPW/AG/LAD
NON PATENT LITERATURE DOCUMENTS Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, dity and/or country where published. Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J. Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
NON PATENT LITERATURE DOCUMENTS Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J.Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
NON PATENT LITERATURE DOCUMENTS Examiner Initials No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J. Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J. Biol. Chem. 271:1761-17165 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Initials No. item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Rabut, G.E. et al., (1991) "Alanine Substitutions Of Polar And Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J. Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Nonpolar Residues In The Amino-Terminal Domain Of CCR5 Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J.Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Differently Impair Entry Of Macrophage And Dualtropic Isolates Of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J.Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Of Human Immunodeficiency Virus Type 1", J. Virol. 72:3464-3468 Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J.Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Raport, C.J. et al., (1996) "Molecular Cloning And Functional Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J.Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Characterization Of A Novel Human CC-Chemokine Receptor (CCR5) For RANTES, MIP-1β, And MIP-1α", J.Biol. Chem. 271:1761-17166 Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Rodriguez, G. et al (1995) "Mediation Of Human Immunodeficiency Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Virus Type 1 Binding By Interaction Of Cell Surface Heparin Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Sulfate Proteoglycans With V3 Region Of Envelope gp120-gp41", J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
J. Virol. 69:2233-2239 Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Rucker, J. et al., (1996) "Regions In B-Chemokine Receptors CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
CCR5 And CCR2b That Determine HIV-1 Cofactor Specificity", Cell 87:437-446 Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Ruffing, N. et al., (1998) "CCR5 Has An Expanded Ligand-Binding Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells", Cell. Immunol. 189:160-168
Repertoire And Is The Primary Receptor Used By MCP-2 On Activated T-Cells*, Cell. Immunol. 189:160-168
Activated T-Cells*, Cell. Immunol. 189:160-168
Altering Antigen-Binding Specificity", Proc. Natl. Acad. Sci. 79:1979-1983
Rusche, J.R. et al., (1988) "Antibodies That Inhibit Fusion Of
Human Immunodeficiency Virus-Infected Cells Bind A 24-Amino
Acid Sequence Of The Viral Envelope gp120*, Proc. Natl. Acad. Sci. 85:3198-3202
Sagg, M. (1997) "Clinical Spectrum Of Human Immunodefilency
Virus Diseases* AIDS: Biology, Diagnosis, Treatment And Prevention, Lippincott-Raven Publishers, Philadelphia, Pp. 203-213
Sandberg, J. and Slikker, W., (1995) "Developmental Pharmacology And Toxicology Of Anti-HIV Therapeutic Agents: Dideoxynucleosides", FASEB J. 9:1157-1163
Sandstorm, E.G. And Kaplan, J.C., (1987) "Antiviral Therapy In
AIDS: Clinical Pharmacological Properties And Therapeutic
Experience To Date", Drugs 34:372-390
Sato, A.I. et al., (1992) *Anti-CD7 Reagents Inhibit HIV-1 Induced Syncytium Formation," International Conference On AIDS. 81. PAS Poa 2017
Sato, A.I. et al., (1994) "Identification Of CD7 Glycoprotein
As An Accessory Molecule In HIV-1 Mediated Syncytium Formation
And Cell Free Infection", J. Immunol. 152:5142-5152
Sato, A.I. et al., (1995) "A Simple And Rapid Method For Preliminary Evaluation Of In Vivo Efficacy Of Anti-HIV
Compounds In Mice*, Antivir. Res. 27:151-163
EXAMINER \ DATE CONSIDERED \
EXAMINER: Initial is citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance

*EXAMINER: Initial it citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. It clide copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). Applicant is to place a checkman where if English language Translation is attached.

				Page 16	or 18
Form PT	0-144	9 U.S. Départment of Commerce		09/460,216	
		Patent and Trademark Office	Filing Date	December 13, 1999	
			First Named Inventor	Graham P. Allaway	et al.
INFORM	ATIO	N DISCLOSURE CITATION	Art Unit	1648	
(Use severa	i sheets	if necessary)	Examiner Name	Jeffrey S. Parkin	
			Attorney Docket No.	50875-F-PCT	
			<u> </u>	US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS	•	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, cutalo publisher, city and/or countr	og, etc.) date, page(s), volur		T ²
		Schanberg, L.W. et al., (1995) *C Transgenic Mice", J. Of Immunol.	haracterization 155: 2407-2418		
0		Schmidtmayerova, H. et al., (1993) PAR, A Macrophage-Tropic Strain: C And Nucleotide Sequence Of The Env In Virology 144(1):21-26	ell Tropism, Vir velope Glycoprote	us/Cell Entry ein. <i>Research</i>	
		Schols, D. et al., (1990) "Dextran Anti-HIV Compounds Specifically In Glycoprotein Expressed By T-Cells HIV-1", Virol. 175:556-561	nteract With The	Viral gp120	
		Schols, D. et al., (1991) "Selec Polyhydroxycarboxylates Derived Fr Human Immunodeficiency Virus Rep Defic. Synd. 4:677-685	om Phenolic Comp plication", J.	ounds Against Acq. Immune	
		Schols, D. et al., (1999) "CD26-Pro Intact RANTES, Has Potent Anti-HIV 30:175-187	/-1 Activity", A	ntiviral Res.	
		Sinangil, F. et al., (1988) "Quant Between Human Immunodeficiency Vi Membrane Fluorescence Dequenching"	rus And Cultured	l Cells Using	
·		Sommerfelt, M.A. et al., (199) Molecule 3, A Candidate Human Immu Receptor On Lymphoid And Monocyt 76:1345-1352		us Type 1 Co-	٠
		Stein, D.S. et al., (1993) Scientific Rationale And Promising Of The Human Immunodeficiency Viru Infect. Dis. 17:749-771		The Treatment	
		Steinberger, P. et al., (2000) *Ge Of A Recombinant Human CCR5-Specif 275:36073-36078	ic Antibody", J	. Biol. Chem.	
		Stewart, G.J., (1997) "Increase Heterozygotes Among Long-Term Infection", AIDS 11:1833-1838	Non-Progressors	With HIV-1	
		Strizki, J.M. et al., (1997) "A Directed Against CXCR4 Inhibits In Human Immunodeficiency Virus Type The T-Tropic Isolate HIV-1 Hxb",	nfection With The 1 Isolates HIV-1	Dual-Tropic 89.6 But Not	
		Su, S.B. et al., (1996) "Prepara Antibodies To A C-C Chemokine Rece Of CCR1 Expression On Various Type Biol. 60:658-666	tion Of Specifi ptor, CCR1, And es Of Leukocytes	c Polyclonal Determination " J: Leukoc.	
		Szabo, G. Jr. et al., (1993) "Spec Bound Anti-LAM-1 (Anti-Sel Aurintricarboxylic Acid, <i>" Molecula</i>	ectin) Antil	oodies By	-
EXAMINE SIGNATUR		DATE CONSIDERED VI	12/2007		

*EXAMINER: Initial if clation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.

		6.3	\mathcal{O}	Page 17	of 19	
Form PI	'()-144	9 U.S. Department of Commerce	Application Number	09/460,216	* 1 	
1		Patent and Trademark Office	Filing Date	December 13, 1999		
			First Named Inventor	Graham P. Allaway	v et al.	
INFORM	1ATIC	ON DISCLOSURE CITATION	Art Unit	1648		
1		s if necessary)	Examiner Name	Jeffrey S. Parkin		
Ì		• •	Attorney Docket No.	50875-F-PCT		
				US/JPW/AG/LAD		
	· · · · · · · · · · · · · · · · · · ·	NON PATENT LITERATURE	DOCUMENTS			
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Initials No. item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
X		Thali, M. et al., (1992) "Coo Antibodies Directed Against The V The Human Immunodeficiency Virus of J. Acq. Immun. Defic. Synd. 5:591	perativity Of S And CD4 Bindi pp120 Envelope G	ng Regions Of		
		Tilley, S. A. (1992) "Synergistic Human Monoclonal Antibodies Again Binding Site gp120", AIDS Resea 80:4:461-467	Neutralization st The V3 Loop	And The CD4-		
		Tilley, S. A. et al., (1991) "Pote Human And Chimpanzee Monoclonal Three Distinct Epitope Clusters Of Cent Gardes. 211-216	Antibodies Dire	cted Against		
		Travis, B.M. et al., (1992) *F Hypervariable Region Of HIV-1 gplo And In The Formation Of Syncytia I 186:313-317	00 In The Proces n CD4-Positive C	sing Of gp160 ells", Virol.		
		Tremblay, C.L. et al. (2000) "Stro Between The Fusion Inhibitor T-2 3100.", 7th Conference On Retr Infections Abstract 500	0 And A CXCR4	Blocker AMD-		
		Tremblay, C.L. et al., (1999) "Str The Fusion Inhibitor T-20 And The Acq. Immun. Defici. Synd. 25(2)99-	CXCR4 Blocker	nergy Between AMD-3100°, J.		
		Trkola, A. et al., (2001) "Potent, Human Immunodeficiency Virus Type Antibody PRO 140", J. Virol. 75:57	Broad-Spectrum e 1 By The CCR	Inhibition Of 5 Monoclonal		
		Trkola, A et al (1999) "Cross-Clad Isolates Of Human Immunodeficier Monoclonal Antibodies And Tetra 69:6609-6617	de Neutralization ncy Virus Type meric CD4-IgG°	1 By Human , J. Virol.		
		Trkola, A. et al., (1998) "Neutral Immunodeficiency Virus Type 1 Pri And CD4-based Reagents Is Independ Virol. 72:1876-1885	mary Isolates 1 lent Of Corecept	o Antibodies or Usage", J.		
		Tulip, W.R. et al., (1992) "Cryst Neraminidase-Antibody Complexes Wi In The Interface", <i>J. Mol. Biol.</i> 2	th Amino Acid S			
		Valentin, A. et al., (1990) Glycoprotein CD18 Participates Formation In Monocytoid And T Cell	"The Leukocy In HIV Inductions", J. Immunol.	ed Syncytia 144:934-937		
		Valenzuela, A. et al., (1997) "Neu The V3 Loop Of Human Immunodefici	tralizing Antib	odies Against		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

Virol. 71(11):8289-8298

EXAMINER

SIGNATURE

Antibodies", AIDS 7:167-174

CD4-Dependent And Independent Binding Of Virus To Cells", J.

Vanini, S. et al., (1992) "Discrete Regions Of HIV-1 gp41 Defined By Syncytia-Inhibiting Affinity-Purified Human

			.,	· · · · · · · · · · · · · · · · · · ·						
Form PT	'0-14 4	9 U.S. Department of Commerce	Application Number	09/460,216						
		Patent and Trademark Office	Filing Date	December 13, 1999						
			First Named Inventor	Graham P. Allaway et al.						
INFORM	IATIO	ON DISCLOSURE CITATION		1648						
(Use several sheets if necessary) Examiner Name Jeffrey S. Pa										
	Attorney Docket No. 50875-F-PCT									
				US/JPW/AG/LAD						
	NON PATENT LITERATURE DOCUMENTS									
Examiner										
Initials	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
		Verrier, F.C. et al., (1997)		To Several						
		Conformation-Dependent Epitopes O	f gp120/gp41 In	hibit CCR-5-						
		Dependent Cell-To-Cell Fusion Medi	iated By The Nat	ive Envelope						
∕~Y		Glycoprotein Of A Primary Macrop	hage-Tropic HIV	-1 Isolate",						
$igcup_{}$		Proc. Natl. Acad. Sci. 94:9326-933								
		Vijh-Warrier, S, (1996) "Synergis	tic Neutralizat	ion Of Human						
}		Immunodeficiency Virus Type 1 E Antibody Against The V2 Domain On	sy A Chimpanzee	Monocional						
		Monoclonal Antibodies Against The	r dbisn in comp	ination with						
	•	Site", J. Virol. 70:4466-4473	vs boop and the	CD4-BINGING						
		Vila-Coro, A.J. et al., (2000) "1	HIV-1 Infection	Through The						
		CCR5 Receptor Is Blocked By Receptor	or Dimerization"	. Proc. Natl.						
		Acad. Sci. 97(7):3388-3393		i						
		Vita, C. et al., (1999) "Rational	Engineering Of A	Miniprotein						
		That Reproduces The Core Of The CD4	4 Site Interactin	ng With HIV-1						
		Envelope Glycoprotein", Proc. Natl	l. Acad. Sci. 96	:13091-13096						
		Wang, Z.Q. et al., (1994) "Deletic	on Of T Lymphocy	tes In Human						
		CD4 Transgenic Mice Induced By H	IV-gp120 And gp	120-Specific						
		Antibodies From AIDS Patients", Eu	r. J. Immunol.	24:1553-1557						
		Wanda, P.E., And Smith, J.D., (1	.982) "A General	. Method For						
1 1		Heterokaryon Detection Using Resortion Fluorescence-Activated Cell Sorter	nance Energy Tra	anster And A						
1 1		30(12):1297-1300	, J. Histochem.	& Cytocnem.						
		Weinhold, K.J., et al., (1989) "	HTV-1 m120-Med	iated Immune						
	•	Suppression And Lymphocyte Destruc	tion In The Abse	nce Of Viral						
		Infection", J. Immunol. 142:3091-3	097							
		Wild, C. et al., (1992) "A Syntheti	ic Peptide Inhibi	tor Of Human						
		Immunodeficiency Virus Replicat	ion: Correlati	on Between						
		Solution Structure And Viral Inhi	ibition", Proc.	Natl. Acad.						
		Sci. 89:10537-10541								
l l		Wild, C. et al., (1993) "A Syntheti	c Peptide From F	IIV-1 gp41 Is						
\		A Potent Inhibitor Of Virus Media Res. Hum. Retroviruses 9:1051-1053	ted Cell-Cell F	usion", AIDS						
-		Wild, C. et al., (1994) "Peptides C		A Dradiation						
		Alpha-Helical Domain Of Human Imm	orresponding To	A Fredictive						
		gp41 Are Potent Inhibitors Of Vir	cus Infection"	Proc. Nat1						
	!	Acad. Sci. 91:9770-9774	,	. Loc. Matt.						
		Wild, C. et al., (1995) "The Inhibi	tory Activity Of	An HIV Type						
		l Peptide Correlates With Its A	bility To Inte	ract With A						
4		Leucine Zipper Structure", AIDS Res	s. Hum. Retrovir	uses 11:323-						
		325								
EXAMINE	~	DATE CONSIDERED								

*EXAMINER: Initial if criation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

SIGNATURE

Form PT	'O-14	19 U.S. D	epartment of Comn	nerce	Appl	ication Number	09/460,216	
İ			and Trademark Of		Filin	g Date	December 13, 1999	
1					First	Named Inventor	Graham P. Allawa	
INFORM	1ATI	ON DISCLOSURE	CITATION		Art		1648	4
(Use sever	al sheet	s if necessary)			Exar	niner Name	Jeffrey S. Parkin	
ł					Atto	rney Docket No.	50875-F-PCT	
		·			L		US/JPW/AG/LAD	
		NON	PATENT LITERAT	TURE	DO	CUMENTS		•
Examiner Initials	Cite No. ¹	include name of the au item (book, magazine,	thor (in CAPITAL LETT) journal, serial, symposiur publisher, city and/o	n, cutalos	z. etc.) date, pare(s), volum	roprinte), title of the ne-issue number(s),	T ²
		Wu, L. et al.,	(1997) "Intera	ction	Of	Chemokine R	eceptor CCR5	
		With Its Ligan	ds: Multiple Do	mains	Fo	r HIV-1 ap12	Binding And	
		A Single Dom 186(8):1373-13	ain For Chemol	kine	Bin	ding", J.	Exper. Med.	
V			et al., (1994)	"CD	ATA	Cloning And	l Functional	
		Expression Of	Human Monocy	/te (Chen	noattractant	Protein 1	
		Receptor", Bio	chem. Biophys.	Res.	Com	mun. 212:115	6-1162	
4		Ylisastigui, I	. et al., (19	98)	'Syn	thetic Full	Length And	
			NTES Inhibit AIDS 12:977-984	HIV-	Τ	Infection	Or Primary	
					-			
					····	· · · · · · · · · · · · · · · · · · ·		
		·						
ļ								
								
								
	·						į	
								
				 -				
			•					
·		·		1				
EXAMINER IGNATURI			DATE CONSIDERED	u).	2	2007		
ing increasing	ical inch	citation considered, whether ide copy of this form with ne- tere if English language Trans	ii communication to annicant	nce with M	1PEP (609: Draw line through nique citation designation	citation if not in conform on number (optional). ² A	nance pplicant

PTO/S8/08A (04-07) Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

Sheet 1

Under the Paperwork Reduction Act of 1995,

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

29

Art Unit

Complete if Known **Application Number** 09/460,216 Filing Date December 13, 1999 First Named Inventor G.P. Allaway et al. 1648 **Examiner Name** Jeffrey S. Parkin Attorney Docket Number 50875-F-PCT-US

Examiner Cite nitials* No.1		Cite Document Number Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number-Kind Code ^{2 (F Innove)}			Figures Appear
X		^{US-} 6,692,745	02-17-2004	Olson	
V _L		^{US-} 6,797,811	09-28-2004	Gray	
L_		^{US-} 5,126,433	12-21-1989	Maddon	
		^{US-} 5,021,409	06-04-1991	Murrer	
		^{US-} 5,440,021	08-05-1995	Chuntharapai	
		^{US-} 5,504,003	04-02-1996	Haodong Li	
		^{US-} 7,118,859	10-10-2006	V.M. Litwin et al.	
		^{US-} 7,138,119	11-21-2006	W.C. Olson et al.	
		^{US-} 7,060,273	06-13-2006	W.C. Olson et al.	
		^{US-} 7,122,185	10-17-2006	W.C. Olson et al.	
		^{US-} 6,908,734	06-21-2005	T. Dragic et al.	
		^{US-} 2003-0166870	12-23-2004	L. Wu et al.	
		^{US-} 2005-0118677	06-02-2005	C. Combadiere et al.	
		US- 2007-0031408 A1	02-08-2007	W.C. Olson et al.	
		US- 2007-0020280 A1	01-25-2007	W.C. Olson et al.	
		US- 2007-0025983 A1	02-01-2007	V.M. Litwin et al.	
		^{US-} 2007-0026441 A1	02-01-2007	W.C. Olson et al.	
		^{US-} 11/581,944	10-16-2006	W.C. Olson et al.	
4		US- 2006-0194244	08-31-2006	G.P. Allaway et al.	†

		FORE	IGN PATENT DOCU	MENTS			
	Cite No.1		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	П
<u>۸</u>		Country Code ² "Number ⁴ "Kind Code ⁸ (# Innown)	MM-DD-YYYY	Approxime of Chicago Coccoming to	Or Relevant Figures Appear	70	
X		WO 07/014114	02-01-2007			Н	
0		WO 94/22477	10-13-1994			Т	
						Г	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents as www.usrbo.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Vind of document by the two-letter code (WIPO Standard ST.3) is conformance as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Signature

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: G.P. Allaway, et al.

Serial No.: 09/460,216 Filed: December 13, 1999

Exhibit B

Date

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 2

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

e as many sheets as necessary)	Examiner Name	ē
laa-		-

Co	mplete if Known	
Application Number	09/460,216	
Filling Date	December 13, 1999	
First Named Inventor	G.P. Allaway et al.	
Art Unit	1648	
Examiner Name	Jeffrey S. Parkin	_
Attorney Docket Number	50875-F-PCY-US	

			U. S. PATEN	F DOCUMENTS	•
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f Income}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 7,151,087 B2	12-19-2006	C. Combadiere et al.	
VI		US- 2006-0233798	10-19-2006	G.P. Allaway et al.	
<u> </u>		US- 2007-0048820	03-01-2007	G.P. Allaway et al.	
		US-			
		US-			
		US-			
		US-		·	†
		US-			
		US-			 -
		US-			
		US-			-
		US			
		US-			,
		US-			
		U\$-			
		US-			
		US-			
		US	1		
$\overline{}$		US-	 	·	

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т
		Country Code ³ Number ⁴ "Kind Code ³ (# known)	MM-OD-YYYY		Or Relevant Figures Appear	ו
			 			
						₽
						ŀ
		N. C.				
						Г

*EXAMINER: Initial (reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if hot in conformance and not considered. Include topy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sorial number of the patent document. 'Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language

Considered

Traisation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 3 Attorney Docket Number 29 50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T ²
X		PCT International Preliminary Examination Report issued October 18, 1996 for International Application Publication No. WO 95/16789	
		PCT International Preliminary Examination Report issued September 5, 1997 for International Application Publication No. WO 96/41020	
		PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
		PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
		PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
		PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
		PCT International Search Report issued March 13, 1995 for International Application Publication No. WO 95/16789	
		PCT International Search Report issued October 10, 1996 for International Application Publication No. WO 96/41020	
		PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
4		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	

-			1		L
Examiner		Date			
Signature	i ' \	Date	1 * <i>1</i>	- 1	_
Signature		Considered	u_{I}	ロフィ	2007
'EXAMINER' I	itial & conference providenced whether a constitution is				/ 200 /

ether or not citation is in conformance with MPEP 609. Draw line through citation if right in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if nift in conformance and not considered. Include copylor this form with next communication to applicant.

1 Applicant's unique challon designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many shoots as necessary) **Examiner Name** Jeffrey S. Parkin Sheet **Attorney Docket Number**

29 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
		PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
		PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
		PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Search Report issued February 24, 2000 for European Patent Application No. 96921473.3	
		European Supplementary Search Report issued September 5, 2002 for European Patent Application No. 95905987.4	
7		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	

Examiner Date Signature Considered *EXAMINER: Initial if refer

nce considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include popy of this form with next communication to applicant.

1 Applicant's unique disting designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ute for form 1449/PTQ				n of information unless it contains a valid QMB control number. Complete if Known
1				Application Number	09/460,216
			CLOSURE	Filing Date	December 13, 1999
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she	ata aa i	eressand	Art Unit	1648
			,,	Examiner Name	Jeffrey S. Parkin
Sheet	5	of	29	Attorney Docket Number	50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
2		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995 2005	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	
		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
1		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	

	<u> </u>			
Examiner /		Date Considered	Ü	12/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ite for form 1449/PTO				Complete if Known	
	•			Application Number	09/460,216	
			SCLOSURE	Filing Date	December 13, 1999	
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many sh	nede ne d	acces ann A	Art Unit	1648	
	1000 of many and		100,033 cm 	Examiner Name	Jeffrey S. Parkin	
Sheet	6	of	29	Attorney Docket Number	50875-F-PCT-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
\gg		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1ß Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling Virology, 234:340-348	
·		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives When Used Proc. Natt. Acad. Sci., 92:5470-5474	
		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
1		Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	

Examiner	Date	\Box	
0:	Dute	١ ١	\
Signature	Considered	111	しいとつかつ
*EVANINED- Initial Management of the state o		V.	100

^{*}EXAMINER: Initial if reference chosidered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of the-form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducins for reducins should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
			Application Number	09/460,216		
				Filing Date	December 13, 1999	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(lita as many she	este ac	teresend	Art Unit	1648	
				Examiner Name	Jeffrey S. Parkin	
Sheet	7	of	29	Attorney Docket Number	50875-F-PCT-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78	
<u> </u>		Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type Proc. Natl. Acad. Sci., 87:6574-6578	
	·	De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of Proc. Natl. Acad. Sci., 89:5286-5290	
_		De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam Antimicrobial Agents and Chemotherapy, 38:668-674	
		De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
		Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
		Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta. Med. Croatica, 50:163-168	
		Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
		Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
4		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	

Examiner	, , , , , , , , , , , , , , , , , , ,	Date			
	′ _1	Date		1	
Signature		Considered	١.	1	2
			l ll	ハン	2007
"EXAMINER: In	tist if reference considered, whether or not citation is in conference				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007, OMB 0651-0031

Substitute for form 1449/PTO Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) One of 1995, no persons are required to respond to a collection of information unit	t and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.				
					Complete if Known
1				Application Number	09/460,216
				Filing Date	December 13, 1999
STA	ATEMENT	BYA	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many	sheata as a	ecoseand	Art Unit	1648
	,			Examiner Name	Jeffrey S. Parkin
Sheet	8	of	29	Attorney Docket Number	50875-F-PCT-US

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
iiiiidis	140.	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
\geq		Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	
4		Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877	
		Flexner, C. and Hendrix, C. (1997). "Pharmacology", in AIDS: Biology, Diagnosis,, 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493	
		Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128	
		Gait, M.J and Kam, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
		Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal J. Exp. Med., 181:631-640	
		Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
		Hattori, T., et al. (1989). Involvement Of Tryptase-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
		Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
4		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	

Examiner	Date			
Signature	Date	1 '	4 '	!
Signature	Considered	1 1.	۱. م ا	28n
*EYAMINED: toiting & color	Considered	1 4	$\mu \nu$	1 200

considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

[&]quot;EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if flot in cofformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete If Known			
Application Number	09/460,216		
_	December 13, 1999		
First Named Inventor	G.P. Allaway		
Art Unit	1648		
Examiner Name	Jeffrey S. Parkin		
Attorney Docket Number	50875-F-PCT-US		
Ī	Filing Date First Named Inventor Art Unit Examiner Name		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T,
X		Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
<u> </u>		Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
		Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
		Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A J. Virol., 70(9):6437-6441	
		Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That is Highly Expressed in Leukocytes. J. Biol. Chem., 269:232-237	
		McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is J. Virol., 71:1692-1696	
		Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
		Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	
		Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	

Examiner	\	Date		
l Cianakina I	\ _	Date		l l
Signature		Considered	[\u \ c	2/2007
'EXAMINER: Init	ist if reference experienced whether are not off all - 1-1		10 [200

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Transtation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Management

' Substitu	rte for form 1449/PTO				compress in random,	1
				Application Number	09/460,216	
			SCLOSURE	Filing Date	December 13, 1999	·
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many she	note se i	naces and	Art Unit	1648	
	1000 10 11111/ 1111		·	Examiner Name	Jeffrey S. Parkin	
Sheet	10	of	29	Attorney Docket Number	50875-F-PCT-US	

Examine	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
\geq		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	
		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246- 256	
		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
\perp		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):A2581259-1265	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
1		Szabo, et al. (1992). Cd4 Changes Conformation Upon Ligand Binding. J. Immunol. 149(11):3596-3604	

Examiner \\	Date	_	<u> </u>
Signature	Considered	4/12	12007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MDED and	Drow line therein -	- 14 A	

[&]quot;EXAMINER: Initial if reterinos considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 111 **Attorney Docket Number** 29 50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
21		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	
Ĭ		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gpl20 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yarchoan, et al. (1988). "Clinical Aspects Of", in AIDS: Etiology, Diagnosis,, De Vita, et al., eds., Lippincott-Raven Publishers, Philadelphia. Pp.107-109	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For J. Enzyme Inhibit., 6:99-11	
	_	Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311	
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311	
4		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	

Examiner Signature			Date Considered	W 12	2087
*EXAMINER: In	itlet i refere	ace considered, whether or not citation in in conformance with MATCO CO		 	1

nce with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include sopy at this form with next communication to applicant.

1 Applicant's include citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Pageneral Reduction Act of 1995, no necessary are a

	ate for form 1449/PTO				Complete If Known
			·	Application Number	09/460,216
1			SCLOSURE	Filing Date	December 13, 1999
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she	wie ne r	norseand	Art Unit	1648
	1000 to many and			Examiner Name	Jeffrey S. Parkin
Sheet	12	of	29	Attorney Docket Number	50875-F-PCT-US

			NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
\searrow			August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	
			July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
			November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	
			July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
			November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
			September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
			September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
			March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		,	February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
1	7		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner 1	· \	Date	1		
10	1	Dute	ı	I	
Signature /	^ I _	Considered		1.2	(2 <i>8</i> 2)
ATTIANA MINISTRA ANTONIO				<u> </u>	001

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through distion is not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique signion designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This coflection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. CMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTQ **Application Number** 09/460,216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet **Attorney Docket Number** 13 29 50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
7		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601	
		August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601	
		March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601	
		June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601	
		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284	
		December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
1		February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284	

Examiner			Date			
Signature	`		Considered		112	2007
FEVAMINED: In	ising is also	and an annual decrease of the second		~		1001

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. ON ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE · Under the Penerunit Reduction Act of 1995, no nemons are required to a

Substit	ute for form 1449/PTO				Complete if Known	
				Application Number	09/460,216	
INF	ORMATION	N DIS	SCLOSURE	Filing Date	December 13, 1999	
STA	ATEMENT I	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many sh		terrenand	Art Unit	1648	***
	(Ooy as many an		rocessary)	Examiner Name	Jeffrey S. Parkin	
Sheet	14	of	29	Attorney Docket Number	50875-F-PCT-US	

			NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
2		,	April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284	
			September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
			December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284	
			April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963	
			December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963	
			February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356	
		_	May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356	
			October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356	
			July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356	
1	,		November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356	

				<u> </u>	
Examiner \	\	Date		1	
Cianatura)	Dute .	1 . 1	1000	
Signature	1	l Considered	1 10112	ו עשיג	
*EYAMINED: Initial Manage			1 1/	1 500	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include clopy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 15 **Attorney Docket Number** 29 of 50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials* Cite No. Include name of the author (in CAPITAL LETTERS), title of the article the item (book, magazine, journal, serial, symposium, catalog, etc.), do number(s), publisher, city and/or country where put		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		July 1, 2003 Office Action in connection with U.S. Application Serial No.	
		September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	
		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062	
•		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	

Examiner ()	Date		
Signature Signature		1. 1	1 -
Signature	Considered	1171 6	212007
EXAMINER: Initial if reference considered, whether or not citation is in a section or in 1955.		101 6	2 \ 000

[&]quot;EXAMINER: Initial if efference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation/lif not in conformance and not considered. Include colly of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

16

29

	1-2-	NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
X		August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062		
		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062		
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062		
	_	September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062		
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062		
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346		
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684		
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616		
		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682		
4		November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	2	

			L
Examiner / _	Date		
Signature			_
Signature	Considered	11/10	200
*EYAMINED: Initial Basessan annidated to the state of the		$-\omega \cap \nu$	100

ered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include body of this form with next communication to applicant.

Applicant is unique disting designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031

<u>U</u>	nder the Paperwork R	eduction A	ct of 1995, no persons a	re required to respond to a collection	of information unless it contains a valid OMB control	MMERCE Loumber
Substitute for form 1449/PTO				Complete if Known		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09/460,216	
				Filing Date	December 13, 1999	
STA				First Named Inventor	G.P. Allaway	
1	(Lise as many s	haata sa <i>i</i>	eres sand	Art Unit	1648	
	(Uso as many sheets as necessary)			Examiner Name	Jeffrey S. Parkin	
Sheet	17	of	29	Attorney Docket Number	50875-F-PCT-US	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	_
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
X		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
		May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
J		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

Examiner	1	. I D	Date			
Cimana	\	ا ا	Jake	1	_	
Signature		1 (Considered	1.110	1 2 AV	
				ユリハン	(200)	
"EXAMINER: In	itial if reference considered whether	res not citation is in conformance with MOED can. F	Down line the start			_

[&]quot;EXAMINER: Initial if reference considered, whether exact citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique station designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031

50875-F-PCT-US

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet 18

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
7		February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
		May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
		July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
		July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
		November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
	-	December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
1		April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

				.
Examiner 1	Date			
10	1 2000	i	1	
Signature	Considered	I ۱۸.	しょつし	12037
SEXAMPLED AND IS ALL THE SECOND OF THE SECON	Considered	W	10	1 900

EXAMINER: Initial if reference considered, whether or not distion is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copylot/this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is ettached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin-

Attorney Docket Number

Sheet

19

			
E	Lou	NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\searrow		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823	
<u> </u>		December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078	
		December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078	
•		March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	

				1
Examiner \	Date			
Signature				l
TEVANISTE	Considered	l VL	ハマ	12007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citating designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Jeffrey S. Parkin

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number, Complete if Known Substitute for form 1449/P,TO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648

Attorney Docket Number

Examiner Name

(Use as many sheets as necessary)

of 29

Sheet

20

	- 10%-	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examine Initials*	er Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
\nearrow		June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
0		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	
1		September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	

Examiner Signature Considered

EXAMINER: Initial if efference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include clay is this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 21 **Attorney Docket Number** 29 of 50875-F-PCT-US

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
X		February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
		February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
		February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
		August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
		November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
		May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
		September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
		December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
		March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	
٨		September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	

Examiner	! <u>\</u>	Date		
Signature /			1 1	1 _
Signature		Considered	112112	12007
*EVASSISTED: Initial ideal	arence considered, whether or not citation is in conformance with MPEP An		レルルン	100
	Bigrico Considered, whether of not charlon is in conformance with MPFD An	O Draw line through a	itention if not in .	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation is gign designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completated application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PTC)			Complete if Known	1
1				Application Number	09/460,216	
INF	ORMATIO	N DIS	SCLOSURE	Filing Date	December 13, 1999	_
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway	_
	(Use as many s	haata na r	1000 gand	Art Unit	1648	_
	(eve de meny a			Examiner Name	Jeffrey S. Parkin	
Sheet	22	of	29	Attorney Docket Number	50875-F-PCT-US	7

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
2		May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
O_{L}		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
		September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
		November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	-
		May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
		November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
		September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	
		October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	

Examiner	7		Date				
Signature			Considered	16	ハン	12007	
*EXAMINER: In	itial if reference	considered whether or not citation is in conformation with MRED con	Describes their about	10 - 01 -	1	1 	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation pesignation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons at	U.S. Peter re required to respond to a collection	nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it contains a valid OMB control number
Substitute for form 1449/PTO		Complete if Known
	Application Number	09/460,216
INFORMATION DISCLOSURE	Filing Date	December 13, 1999
STATEMENT BY APPLICANT	Application Number 09/4 COSURE Filling Date Dec PLICANT First Named Inventor G.F. Art Unit 164	G.P. Allaway
(Use as many sheets as necessary)	Art Unit	1648
, and an indicate any	Examiner Name	Jeffrey S. Parkin

Attorney Docket Number

Sheet

23

			NON PATENT LITERATURE DOCUMENTS	
Exam Initial		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
\gtrsim			April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
			February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
			March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	
		-	March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
			March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
			January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
			October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
			January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
			October 13, 2005 Office communication in connection with Mexican Application No. 1006097	
¥	,		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902	

أحرب والمستواحين						
Examiner		Date	- 1			
Signature /	4.	Considered	1		2007	
PEVALUNED: Initial Marks		1 000000000	1.4	1.0	100	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to fits (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 24 Attorney Docket Number

Exan	niner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of		
Initials* No.1			the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
			January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902		
			April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902		
			October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902		
			June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902		
			January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902		
			April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902		
			October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902		
			September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902		
		٠	August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983		
	1		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983		

Examiner	—	Date		
C:		Date	1 1	l
Signature /		Considered	11.110	1000
SEVALABLES. Later		Considered	しいいて	12007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique it also designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retian a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

25

Examiner	Cito	NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983		
7		August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983		
		September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983		
		December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983		
		March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983		
		September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983		
		December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545		
		July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545		
		June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545		
1		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545		

				t
Examiner	\	Date		
Cinnos	4	Date	l 1	1
Signature		Considered	14/12	12007
*EYAMINED: In	ial if reference considered, whether or not citation is in conformance with MRED co		16160	1.00 I
EATHIREN, III	PSF II IDIGITATION CONSIDERED, Whether Or not citation is in conformance with MDCO co.	O Down Fan there al	4-1-1	

EXAMINER: Initial if inference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 09/30/2007. OMB 0651-0031

لاسر	inder the Paperwork Re	duction /	Act of 1995, no persons a	U.S. Patent re required to respond to a collection	t and Trademark Office; U.S. DEPARTMENT OF COMMERCE n of information unless it contains a valid OMB control number.
	tute for form 1449/PTO				Complete if Known
				Application Number	09/460,216
			SCLOSURE	Filing Date	December 13, 1999
ST	ATEMENT E	3Y A	PPLICANT	First Named Inventor	G.P. Allaway
	(Uso as many sh	ets as i	ecessen/i	Art Unit	1648
				Examiner Name	Jeffrey S. Parkin
Sheet	26	of	29	Attorney Docket Number	50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of		
Initials* No.1		the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
25		April 21, 2006 Supplementary European search report under Article 157 (2)(a) in connection with European Application No. 03 713 632.2		
1		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938		
		May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483		
		October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483		
		January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674		
		February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	_	
		October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2		
	:	March 14, 2006 Examination Report in connection with New Zealand Application No. 534947		
		February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)		
4		September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8		

Examiner			<u> </u>	<u> </u>
L'YOUNIEL	' -	Date	1	
Signature		June 1	1 .	١
Signature		Considered \	いいつ	1.267
PEYAMINED. L		Considered	<i>0 \ C</i>	γ α D I
CAMBINER, IN	itial if reference considered, whether or not citation is in conformance with MPEP BOS	Drow line through sitesia.		

[&]quot;EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include loopy of this form with next communication to applicant.

Applicant's unique station designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete linis form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

50875-F-PCT-US

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

27

	-					
			NON PATENT LITERATURE DOCUMENTS			
		Cite No. ¹				
D	√		August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219			
Ĭ			January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824			
			January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824			
			April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824			
			July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824			
			July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925			
			June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925			
		,	May 24, 2006 Supplementary European search report under Article 157(2) (a) EPC in connection with European Application No. 01970984.9			
			February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9			
`	4		May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9			

			
Examiner	\\	Date	
	· \ _	Date	1 1
Signature		Considered	
9		Considered	$\mathcal{M}(\mathcal{L})$ \mathcal{L}
SEVASABLED. L	DISTANCE (COMPANY)		$\mathcal{O}(1, \mathcal{O}(1, \mathcal{O}$

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if riet in conformance and not considered. Include colly of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is ettached. This conformation is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

28

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS		
Initials*	The strains of the deliter (in Oct 1175 FF1 (EVO), (ille of the strick (when shown sign))		itle of issue T	
Y		October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615		
<u> </u>		September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	·	
		March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615		
		September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615		
		February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615		
		September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615		
	-	February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615		
		June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615	_	
		June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797		
4		April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797		

C						
Examiner	\ \		Date			
C:	' '		Date	,		
Signature	\sim 1 -	_	Considered	l	ا ۔ ا	12007
<u> </u>	ition it also and a contra		Considered	1 16	ヽ(フィ	(can i

[&]quot;EXAMINER: Initial if interence considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citatiba assignation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiathly is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
stitute for form 1449/PTO

Application Number.

Complete If Known Substitute for form 1449/PTO **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 29 of 29 **Attorney Docket Number** 50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797	
ď		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797	
		·	
	. -		
	,		

			L	•
Examiner \	Date			
Signature		1 1		۱ ـ
	Considered	111	112	1200
"EXAMINER: Initial if reference considered whether or not citation	on is in conformance with MPEP 600. Occur line through a	<u></u>	77-	100

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 09/30/2007. OMB 0651-0331 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Attorney Docket Number 50875-F-PCT-US

Substitute for form 1449/PTO	Complete if Known				
	Application Number	09/460,216			
INFORMATION DISCLOSURE	Filing Date	December 13, 1999			
	First Named Inventor	G.P. Allaway et al.			
STATEMENT BY APPLICANT	Art Unit	1648			
(Use as many sheets as necessary)	Examiner Name	Jeffrey S. Parkin			

of 29

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
X		^{US-} 6,692,745	02-17-2004	Olson	
Υ		^{US-} 6,797,811	09-28-2004	Gray	
		US- 5,126,433	12-21-1989	Maddon	
		^{US-} 5,021,409	06-04-1991	Murrer	
		^{US-} 5,440,021	08-05-1995	Chuntharapai	
		US- 5,504,003	04-02-1996	Haodong Li	
]		US- 7,118,859	10-10-2006	V.M. Litwin et al.	
		US- 7,138,119	11-21-2006	W.C. Olson et al.	
		^{US-} 7,060,273	06-13-2006	W.C. Olson et al.	
		^{US-} 7,122,185	10-17-2006	W.C. Olson et al.	
		^{US-} 6,908,734	06-21-2005	T. Dragic et al.	
		^{US-} 2003-0166870	12-23-2004	L. Wu et al.	
		^{US-} 2005-0118677	06-02-2005	C. Combadiere et al.	
		us- 2007-0031408 A1	02-08-2007	W.C. Olson et al.	
<u> </u>		us- 2007-0020280 A1	01-25-2007	W.C. Olson et al.	,
		US- 2007-0025983 A1	02-01-2007	V.M. Litwin et al.	
		^{US-} 2007-0026441 A1	02-01-2007	W.C. Olson et af.	
		^{US-} 11/581,944	10-16-2006	W.C. Olson et al.	
•		^{US-} 2006-0194244	08-31-2006	G.P. Allaway et al.	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)		Or Relevant Figures Appea		
		WO 07/014114	02-01-2007			┢
X		WO 94/22477	10-13-1994			Г
U						Г
						Œ
	_					

Signature 200 *EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not it conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language

Examiner

Sheet 1

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiatity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Serial No.: 09/460,216 Filed: December 13, 1999 Exhibit A

PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Attorney Docket Number 50875-F-PCT-US

Date

Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date December 13, 1999 INFORMATION DISCLOSURE First Named Inventor G.P. Allaway et al. STATEMENT BY APPLICANT Art Unit 1648 (Use as many sheets as necessary) Examiner Name Jeffrey S. Parkin

Sheet 2

Examiner

Signature

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
X		^{US-} 7,151,087 B2	12-19-2006	C. Combadiere et al.	
		^{US-} 2006-0233798	10-19-2006	G.P. Allaway et al.	
•		US- 2007-0048820	03-01-2007	G.P. Allaway et al.	
		US-			
		US-	<u> </u>		
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ³ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁰
	<u> </u>					
						╙
· · · · · · · · · · · · · · · · · · ·						\vdash
	<u> </u>					${f H}$
	-		 	L	I	

*EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if bot in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.usoto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Vind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/088 (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Attorney Docket Number Sheet 29 50875-F-PCT-US of

			NON PATENT LITERATURE DOCUMENTS	
		Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7			PCT International Preliminary Examination Report issued October 18, 1996 for International Application Publication No. WO 95/16789	
			PCT International Preliminary Examination Report issued September 5, 1997 for International Application Publication No. WO 96/41020	
			PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
			PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
·			PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
			PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
			PCT International Search Report issued March 13, 1995 for International Application Publication No. WO 95/16789	
			PCT International Search Report issued October 10, 1996 for International Application Publication No. WO 96/41020	
			PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
1	,		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	

Examiner Date Signature Considered

[&]quot;EXAMINER: Initial if reference considered, whather or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This cotection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

Approved for use through 08/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) Examiner Name Jeffrey S. Parkin

Attorney Docket Number

29 of

Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
X	1	PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
) _		PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
		PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
		PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Search Report issued February 24, 2000 for European Patent Application No. 96921473.3	
		European Supplementary Search Report issued September 5, 2002 for European Patent Application No. 95905987.4	
J		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	

Examiner	N	Date				
Signature		Considered	h	112	2007	
*FYAMINER: In	tial if reference considered, whether or not citation is in conformance with MPED so	O Demu line through a				4

^{*}EXAMINER: Initial if reference considered, whether on to citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

29

Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
j		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995 2005	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	
		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
4		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	

Examiner	1		Date			
Signature			Considered	lλι	1(2	12007
*EXAMINER: II	nitiet/f refe	rance considered, whether or not citation is in conformance with MPER SC	O Drow line through a	itatia	if and in	the state of the s

considered. Include copy of this form with next communication to applicant.

considered. Include copylor trus form with next communication to appacam.

Applicant's unique Signon designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449/PTO				Complete if Known
0				Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	STATEMENT BY APPLICAN	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many she	oto no s	ooogeand.	Art Unit	1648
	(Coo as many and	013 63 H	ocessary)	Examiner Name	Jeffrey S. Parkin
Sheet	6	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1ß Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
) 		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling Virology, 234:340-348	
		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives When Used Proc. Natl. Acad. Sci., 92:5470-5474	
		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
1		Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	

			1	T .
Examiner		Date		
Signature		Considered	14/12	200
PEYAMINED .	Mind III and annual annual depend on the Abres are not a fault on the Leavest			<u> </u>

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include capy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
rademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork Rec	luction A	ct of 1995, no persons a	re required to respond to a collection	n of information unless it contains a valid QMB control number. Complete if Known
0000010	10.101.10111.1443/F10			Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she			Art Unit	1648
		7013 85 11	ocossai y/	Examiner Name	Jeffrey S. Parkin
Sheet	7	of	29	Attorney Docket Number	50875-F-PCT-US

•			
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Cruse, et al. (1995). illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78	
		Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type Proc. Natl. Acad. Sci., 87:6574-6578	
		De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of Proc. Natl. Acad. Sci., 89:5286-5290	
		De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam Antimicrobial Agents and Chemotherapy, 38:668-674	
		De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
		Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
		Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta. Med. Croatica, 50:163-168	
		Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
		Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
•		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	

Examiner Date Signature Considered

"EXAMINER: Initial if reprend considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if ndt in conformance and not considered. Include cody of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This cotlection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FESS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

29

Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
N		Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	
1		Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877	•
		Flexner, C. and Hendrix, C. (1997). "Pharmacology", in AIDS: Biology, Diagnosis,, 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493	
		Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128	
		Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
		Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal J. Exp. Med., 181:631-640	
		Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
		Hattori, T., et al. (1989). Involvement Of Tryptase-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
		Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
b		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	

l Examiner	' '	•		Date	T	
	7			Date	1 1	4
Signature		_	. 1	Considered	.	
o.gata.o			 •	Considered	1 16 117	2/2017
SEVALULED. L	141 - 114 4					

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line unrough citation is questionally considered. Include copy of this form with next communication to applicant.

1 Applicant's unique vitation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 09/30/2007. OMB 0851-0031

Ur	nder the Paperwork Red	duction A	kat af 1995, no persons s	re required to respond to a collection	of information unless it contains a valid OMB control nu	.ERCE
					Complete if Known	
, 02.00				Application Number	09/460,216	
INF	ORMATION	I DIS	SCLOSURE	Filing Date	December 13, 1999	
STA	Under the Paperwork Reduction Act of 1995, no persons positive for form 1449/PTO IFORMATION DISCLOSURE TATEMENT BY APPLICANT (Use as many sheets as necessary)	First Named Inventor	G.P. Allaway			
	Also so mony ch			Art Unit	1648	
	(Coe as many Sm	PO 63 (Examiner Name	Jeffrey S. Parkin	
Sheet	q		20	Attorney Docket Number	F097E E DOT US	

			VOLUMENT	
			NON PATENT LITERATURE DOCUMENTS	
Exami Initials		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
2		·	Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
Y			Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
			Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
			Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A J. Virol., 70(9):6437-6441	
			Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237	
			McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is J. Virol., 71:1692-1696	
			Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
			Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	
			Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
•	1		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	

			.
Examiner \	Date		
Signature	Considered	412	2007
*EXAMINER: Initial if prigrance chasidered whether or All ritation is in contra-	need with MOCO COO. Describer the second		100/

"EXAMINER: Initial if efference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
D a collection of information unless it contains a collection of information unless it contains.

Substitu	te for form 1449/PTO	_			Complete if Known
•				Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	INFORMATION DISCLOSUR STATEMENT BY APPLICAN (Use as many sheets as necessary)	PPLICANT	First Named Inventor	G.P. Allaway	
:			nonecond/	Art Unit	1648
	(OSC OS MONT SITE	PO45 (45 F	···	Examiner Name	Jeffrey S. Parkin
Sheet	10	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
~		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	
		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246- 256	
		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):A2581259-1265	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
1		Szabo, et al. (1992). Cd4 Changes Conformation Upon Ligand Binding. J. Immunol. 149(11):3596-3604	

Examiner Signature	Date Considered	12	2007
STANABLED: 1:10:1		· 100	1 000 /

*EXAMINER: Initially reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is entached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449/PTO			Complete if Known			
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				Application Number	09/460,216		
INF	ORMATION	I DIS	CLOSURE	Filing Date	December 13, 1999		
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
	(Use as many she	sote no s	and count	Art Unit	1648 ·		
	lose as many and	PO 43 03 11		Examiner Name	Jeffrey S. Parkin		
Sheet	11	of	29	Attorney Docket Number	50875-F-PCT-US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	
		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gpl20 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yarchoan, et al. (1988). "Clinical Aspects Of", in AIDS: Etiology, Diagnosis,, De Vita, et al., eds., Lippincott-Raven Publishers, Philadelphia. Pp.107-109	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For J. Enzyme Inhibit., 6:99-11	
		Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311	
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311	
*		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	

				1
Examiner Signature	\	Date Considered	11/12	2007
ACVADAMED. A.WLIE.				

[&]quot;EXAMINER: Initial If eference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include capy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031

Un	der the Paperwork Red	duction A	ct of 1995, no persons a		of information unless it contains a valid OMB conti	
Substitu	te for form 1449/PTO		• •		Complete if Known	
CEDUL				Application Number	09/460,216	
INF	ORMATION	I DIS	SCLOSURE	Filing Date	December 13, 1999	
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many sh			Art Unit	1648	-
	(Use as many sn	0013 43 1	rocessary)	Examiner Name	Jeffrey S. Parkin	
Sheet	12	of	29	Attorney Docket Number	50875-F-PCT-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	7	August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	
$O_{\mathbf{l}}$		July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
		November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	
•		July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
		November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
		September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
		September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
1		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation testignation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date INFORMATION DISCLOSURE December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

13

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
2		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
) -		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601	
		August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601	
		March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601	
		June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601	
		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284	
		December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
1		February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284	

						•
Examiner		Date				
		Date	l 1	1	B .	
Signature		Considered	l \.	lin l	400	
0.9		Considered	וי ו	ハン	1222	
*EXAMINER: In	itial if reference considered, whether or not citation is in conformance with MPEP at	O Drow line through a	Hothes H	d in on		

EXAMINER: Initial of reference/considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include popy of this form with next communication to applicant.

Applicant's unique ejustion designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

29 of

Sheet 14

F	·	014-	NON PATENT LITERATURE DOCUMENTS	
Exam Initials		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\sum			April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284	
			September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
			December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284	
			April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963	
			December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963	
			February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356	
			May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356	
			October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356	
			July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356	
1		-	November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356	

Examiner		Date			
•	1	2000			A A
Signature	\rightarrow	Considered	T (112	200
			V	100	1 000
SEVABILIED. L	Mal Cardana Ca			_	

^{*}EXAMINER: Initial/fireference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if high in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation/designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/088 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449/PTO				Complete if Known
00000				Application Number	09/460,216
INF	ORMATION	I DIS	CLOSURE	Filing Date	December 13, 1999
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many sh		one and	Art Unit	1648
	(Use as many sin	7413 M3 II	ocossary)	Examiner Name	Jeffrey S. Parkin
Sheet	15	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
\geq		July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356		
	September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415			
		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415		
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415		
·		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415		
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415		
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415		
		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062		
		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062		
4		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062		

		_		L	
Examiner	Date			_	
Signature	Considered	6	1121	200)
45 WAAAINISS A.			\		_

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if rigt in conformance and not considered. Include clop of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation Is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

					Complete if Known
				Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
INFORMATION DISCLOSURE STATEMENT BY ARRIVED AND SUBSTITUTE OF STATEMENT BY ARRIVED AND SUBSTITUTE BY ARRIVED AND SUBSTITU	1648				
	(Ose as many sin	9013 GS 11	iocessary)	Examiner Name	Jeffrey S. Parkin
Sheet	16	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examine Initials*	r Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X		August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062	
		September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062	:
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062	
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346	1
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684	
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616	
·		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682	
1	,	November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	

Examiner		Date				
Signature		Considered	lω	112	2007	

[&]quot;EXAMINER: Initial if leference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Jeffrey S. Parkin

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary)

Attorney Docket Number

Examiner Name

Sheet

Examiner

117

29

of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
2		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
	-	May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
•		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

Signature Considered

Date

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeffrey S. Parkin

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary)

Attorney Docket Number

Examiner Name

Sheet

18

			NON PATENT LITERATURE DOCUMENTS	
Exami Initials		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2			March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
<u> </u>			February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
			May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
			July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
			July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
			November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
			December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
			January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
			September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
	J		April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

		L_	
Examiner	Date		
Signature	Considered	14/13	-12007

EXAMINER: Injulal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if vot in conformance and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for Evoluting this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTC				n of information unless it contains a valid OMB control number. Complete if Known
				Application Number	09/460,216
INF	ORMATIO	N DIS	SCLOSURE	Filing Date	December 13, 1999
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many s	.h.a.t		Art Unit	1648
	(Use as many s	HICOLD 03 I	iocossary)	Examiner Name	Jeffrey S. Parkin
Sheet	19	of	29	Attorney Docket Number	50875-F-PCT-US

			NOVE THE PROPERTY OF THE PROPE	
Exam Initials		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	X		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823	
			December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
			August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
			June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938	
			September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
			August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
			May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
			June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078	
			December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078	
A			March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	

Examiner		Date		
	'_ \	Date		.
Signature		Considered	1,1,2	2057
L Signature				<i>uu 1</i>

^{*}EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include popy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of infortation is fequired by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date INFORMATION DISCLOSURE December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

29

Sheet 120

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\searrow	•	June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
0,		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	
,127,8	3	September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	

Date Examiner Considered Signature

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

EXAMINER: Initial if reference consistents, whether of not-sitation is in conformance with MPEP 609. Draw line through distain if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information of required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999

STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin **Attorney Docket Number** Sheet 21 29 50875-F-PCT-US

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
	February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
	February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
	August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
	November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
	May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
	September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
	December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
	March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	
	September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
		No.¹ the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98 February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98 February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090 August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618 November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618 May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618 September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618 December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105 March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105 September 23, 2004 Office Action in connection with U.S. Application Serial No.

				.	L
Examiner	, /	Date		1	
Signature		Considered	W	12	120)

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique station designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO				n of Information unless it contains a valid OMB control number. Complete if Known
-				Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she	ate ce r	acces sand	Art Unit	1648
	(Uso as many and	010 00 11	acussary)	Examiner Name	Jeffrey S. Parkin
Sheet	22	of	29	Attorney Docket Number	50875-F-PCT-US

			NON PATENT LITERATURE DOCUMENTS	
Exam Initials		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	L ₅
2		•	May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
	1		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
			August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
			May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
			September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
			November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	
			May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
			November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
			September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	
1	Y		October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	

Ex	caminer	\	Date				
Sig	gnature		Considered	lλι	1,2	2897	
*F)	CAMINER I	itially reference considered, whether or not citation is in conformaces with MDEO con	Demar II nor About and a		A		_

[&]quot;EXAMINER: Initial/if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Jeffrey S. Parkin

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date **INFORMATION DISCLOSURE** December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name**

Attorney Docket Number

Sheet

23

29

of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
examiner Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
χ		April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
1		February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
		March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
		January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
	1	October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
		January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
		October 13, 2005 Office communication in connection with Mexican Application No. 1006097	
1		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902	

Examiner	4	Date	_	1	
Signature			[[[]	100	240
Oignature		Considered		100	((100)

EXAMINER: Initial invelorence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date INFORMATION DISCLOSURE December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

24

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Y		January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902	
1		April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902	
		June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902	
		January 13, 2005 Final Office Action in connection with U.S. Application Senal No. 09/464,902	
		April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902	
		September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902	
		August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983	
7		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983	

Examiner	Date		
Signature	Considered	1.112	1200)
PEVALUED. 1			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique chation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidermatility is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

25

of 29

				NON PATENT LITERATURE DOCUMENTS	
	Exan Initia		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
1				July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
	Y			August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983	
				September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983	
				December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
				March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983	
				September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983	
				December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545	
				July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
				June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
	1	,		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	

Examiner Signature		Date Considered	11/12	200
*EXAMINER: I	nitial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through citati	on if bot in co	nformance and not

considered. Include copy of this form with next communication to applicant.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Jeffrey S. Parkin

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary)

Attorney Docket Number

Examiner Name

29

Sheet 26

	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	April 21, 2006 Supplementary European search report under Article 157 (2)(a) in connection with European Application No. 03 713 632.2	
	September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
i I	May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483	
	October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483	
	January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674	
	February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	
	October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2	
	March 14, 2006 Examination Report in connection with New Zealand Application No. 534947	
	February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)	
	September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. April 21, 2006 Supplementary European search report under Article 157 (2)(a) in connection with European Application No. 03 713 632.2 September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938 May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483 October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483 January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674 February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2 October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2 March 14, 2006 Examination Report in connection with New Zealand Application No. 534947 February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation) September 29, 2006 Grant of Patent in connection with Singaporean Application

Examiner Date Signature Considered

EXAMINER: Initial if fetrence originates, whether er not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include dopy of this form with next communication to applicant.

1 Applicant's unique dilation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date INFORMATION DISCLOSURE December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin **Attorney Docket Number** Sheet 27 29 50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219	
		January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824	
		January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824	
		April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925	
		June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925	·
		May 24, 2006 Supplementary European search report under Article 157(2) (a) EPC in connection with European Application No. 01970984.9	
		February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9	
4		May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9	

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeffrey S. Parkin

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary)

Attorney Docket Number

Examiner Name

Sheet 28 of 29

, , , , , , , , , , , , , , , , , , , ,		NON DATENT LITEDATUDE DOCUMENTS		
Examin Initials*		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
X		October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615		
0		September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615		
		March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615		
		September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615		
		February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615		
		September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615		
		February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615		
		June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615		
		June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797		
`	6	April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797		

Examiner Signature		1	Date Considered	1,	1.2	200	<u> </u>
					112	1000	/
*EXAMINER: II	nitial if refe	egence considered, whether or not citation is in conformance with MPEP 609	Draw line through o	itation i	f bof in cor	formance and	oot

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is ettached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SE/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a veild QMB control number. Complete If Known Substitute for form 1449/PTO **Application Number** 09/460.216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin **Attorney Docket Number** Sheet 29 29 50875-F-PCT-US of

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volum number(s), publisher, city and/or country where published.				
X		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797		
Y		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797		
		·		
			÷	
		·		
		·		
-				
		·		
		·		
	L			

Signature Considered *EXAMINER: Initial traference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not

Date

Examiner

reconsidered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.